{"matching_results": 24891, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1868, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1530}, {"key": "negative", "matching_results": 333}, {"key": "neutral", "matching_results": 5}]}]}, {"key": "tickerreport.com", "matching_results": 751, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 637}, {"key": "negative", "matching_results": 113}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 731, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 524}, {"key": "negative", "matching_results": 207}]}]}, {"key": "thelincolnianonline.com", "matching_results": 722, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 518}, {"key": "negative", "matching_results": 204}]}]}, {"key": "freelancer.com.co", "matching_results": 677, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 631}, {"key": "negative", "matching_results": 46}]}]}, {"key": "theolympiareport.com", "matching_results": 661, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 451}, {"key": "negative", "matching_results": 210}]}]}, {"key": "wkrb13.com", "matching_results": 609, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 490}, {"key": "negative", "matching_results": 119}]}]}, {"key": "dailypolitical.com", "matching_results": 441, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 377}, {"key": "negative", "matching_results": 64}]}]}, {"key": "findmarketresearch.org", "matching_results": 425, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 359}, {"key": "negative", "matching_results": 65}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 365, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 293}, {"key": "negative", "matching_results": 72}]}]}]}], "results": [{"id": "prMJnFrWrog9AgtEPjBfAkKQQOXdBivDgDtGmulWoZ_eA-fwLsn1zGJAhv_5qikk", "result_metadata": {"score": 36.77536}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.896398, "label": "/finance/investing"}, {"score": 0.896398, "label": "/finance/investing/beginning investing"}, {"score": 0.88517, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995975, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.840093, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.191512, "count": 1}]}, "crawl_date": "2018-11-23T12:40:50Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45354691-hbk-investments-lp-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T12:37:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.988692, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.910266, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.83781, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.749921, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.679365, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.679365, "type": "Quantity"}], "sentiment": {"document": {"score": -0.418973, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945303, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.805651, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Hedge fund", "relevance": 0.778056, "dbpedia_resource": "http://dbpedia.org/resource/Hedge_fund"}, {"text": "Investment", "relevance": 0.727384, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Collective investment scheme", "relevance": 0.687831, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}, {"text": "Security", "relevance": 0.670192, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Mutual fund", "relevance": 0.64546, "dbpedia_resource": "http://dbpedia.org/resource/Mutual_fund"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.643202, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Name", "relevance": 0.641726, "dbpedia_resource": "http://dbpedia.org/resource/Name"}], "categories": [{"score": 0.810546, "label": "/finance/investing/funds"}, {"score": 0.803437, "label": "/real estate/buying and selling homes"}, {"score": 0.79765, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [302, 307], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [280, 283], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.828157, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.697913, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.647805, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.636224, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624045, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616033, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.74856, "label": "negative"}, "relevance": 0.595763, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.589863, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589451, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.582135, "count": 2}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575932, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.57215, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571749, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569448, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565923, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.565396, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.561557, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560195, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.558148, "count": 5}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555216, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555034, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554596, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554313, "count": 2}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.549906, "count": 1}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.543737, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.542798, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542153, "count": 1}, {"text": "behalf", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.537989, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.537055, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535274, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.532248, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531943, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531839, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529103, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525772, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524157, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522823, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522782, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.521793, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51644, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515011, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512486, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.511867, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.508848, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504983, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.503069, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.500146, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496035, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48919, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.485661, "count": 1}]}, "extracted_metadata": {"sha1": "1302e5c5aab404685c81fc54c295e27d6afa1430", "filename": "1542976850267.zip-f0494a6633b45f107424bd0b27e63e2d.xml", "file_type": "json"}, "title": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "wxhvLvI1HWO057HQT6R3PyZVRZZKtREQ-aAPHDcwn1Mh4opLrvkIw0aePimTy6kX", "result_metadata": {"score": 34.86175}, "author": "PR Newswire (engl.)", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98", "relevance": 0.01, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": -0.804478, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Antidepressant Drugs Market", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Market"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research Seite 1", "object": {"text": "$15.98 Bn", "keywords": [{"text": "Bn"}], "entities": [{"type": "Quantity", "text": "$15.98"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}, {"subject": {"text": "Allied Market Research Seite 1", "keywords": [{"text": "Market Research Seite"}, {"text": "Allied"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research Seite 1", "object": {"text": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Bn"}, {"text": "Globally"}, {"text": "Market"}], "entities": [{"type": "Quantity", "text": "$15.98"}, {"type": "Quantity", "text": "2.1"}]}, "action": {"verb": {"text": "Says", "tense": "present"}, "text": "Says", "normalized": "Says"}}], "concepts": [{"text": "Antidepressant", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}], "categories": [{"score": 0.937842, "label": "/health and fitness"}, {"score": 0.920755, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.737627, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research Seite 1", "score": 0.261322, "arguments": [{"text": "Drugs", "location": [15, 20], "entities": [{"type": "Substance", "text": "Drugs"}]}, {"text": "Market", "location": [21, 27], "entities": [{"type": "Organization", "text": "Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research Seite 1", "score": 0.491137, "arguments": [{"text": "Allied Market Research Seite 1", "location": [84, 114], "entities": [{"type": "Organization", "text": "Allied Market Research Seite 1"}]}, {"text": "Says", "location": [79, 83], "entities": [{"type": "EventCommunication", "text": "Says"}]}]}], "keywords": [{"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.804478, "label": "negative"}, "relevance": 0.990585, "count": 1}, {"text": "Market Research Seite", "sentiment": {"score": -0.804478, "label": "negative"}, "relevance": 0.1569, "count": 1}, {"text": "CAGR", "sentiment": {"score": -0.804478, "label": "negative"}, "relevance": 0.04859, "count": 1}]}, "crawl_date": "2018-11-22T19:57:25Z", "url": "https://www.wallstreet-online.de/nachricht/11031511-antidepressant-drugs-market-to-reach-15-98-bn-by-2023-globally-at-2-1-cagr-says-allied-market-research", "host": "wallstreet-online.de", "text": "Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co.", "main_image_url": "https://assets.wallstreet-online.de/_media/6/nachrichtenfeeds/size_645/logo-pr-newswire-engl.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T14:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.284698, "label": "negative"}, "text": "depression", "relevance": 0.869287, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allied Market Research", "relevance": 0.772243, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.578695, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oregon", "relevance": 0.536375, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PORTLAND", "relevance": 0.522229, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.447283, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.439346, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.427698, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.419237, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.41918, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.408058, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.347629, "label": "positive"}, "text": "Bristol Myers Squibb Co.", "relevance": 0.400945, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.392752, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly and Co.", "relevance": 0.389991, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.385435, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck", "relevance": 0.384611, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.376114, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes Plc", "relevance": 0.375171, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.374775, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": -0.23701, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.336501, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$14.11 billion", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98 billion", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 month", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2023", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.7%", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.9%", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.0%", "relevance": 0.336501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.336501, "type": "Quantity"}], "sentiment": {"document": {"score": -0.571654, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "from depression", "keywords": [{"text": "depression"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "anxiety", "keywords": [{"text": "anxiety"}]}, "sentence": " Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "emergence"}, {"text": "novel drug"}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "stress , and anxiety coupled with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "novel drug"}, {"text": "emergence"}, {"text": "anxiety"}]}, "sentence": " Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "the growth of the antidepressant drugs market", "keywords": [{"text": "antidepressant drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "are expected to boost", "normalized": "be expect to boost"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers in-depth analyses of the global antidepressant drugs market by closely analyzing the industry trends, top investment pockets, drivers & opportunities, key growth strategies, and competitive landscape.", "object": {"text": "in-depth analyses of the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}, {"text": "in-depth analyses"}, {"text": "market"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "for $14.11 billion", "entities": [{"type": "Quantity", "text": "$14.11 billion"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "$15.98 billion by 2023", "entities": [{"type": "Quantity", "text": "$15.98 billion"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "a CAGR of 2.1%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "2.1"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "the development of drugs with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "drugs"}, {"text": "development"}]}, "sentence": " Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "antidepressants", "keywords": [{"text": "antidepressants"}]}, "sentence": " However, poor efficacy and safety profiles of drugs, inclination toward non-pharmacological therapies, and increase in the number of patent expiration of antidepressants hamper the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "object": {"text": "from stress", "keywords": [{"text": "stress"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "lucrative opportunities for the market players", "keywords": [{"text": "lucrative opportunities"}, {"text": "market players"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "action": {"verb": {"text": "create", "tense": "future"}, "text": "are expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "Obsessive- compulsive disorder segment", "keywords": [{"text": "Obsessive- compulsive disorder"}, {"text": "segment"}]}, "sentence": " Obsessive- compulsive disorder segment to portray fastest demand through 2023", "object": {"text": "fastest demand", "keywords": [{"text": "fastest demand"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "to portray", "normalized": "to portray"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "the fastest CAGR of 2.9%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.9"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "for better quality of life", "keywords": [{"text": "better quality"}, {"text": "life"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}, {"subject": {"text": "the major depressive disorder segment", "keywords": [{"text": "depressive disorder segment"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "diagnosed with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "diagnose", "tense": "past"}, "text": "are diagnosed", "normalized": "be diagnose"}}, {"subject": {"text": "The other segments", "keywords": [{"text": "segments"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "generalized anxiety disorder, panic disorder, and others", "keywords": [{"text": "panic disorder"}, {"text": "anxiety disorder"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "object": {"text": "The other segments analyzed in the report", "keywords": [{"text": "segments"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment to lead the market by 2023", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "to lead", "normalized": "to lead"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "projected to manifest the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "manifest", "tense": "future"}, "text": "is projected to manifest", "normalized": "be project to manifest"}}, {"subject": {"text": "these"}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "highly effective in treat depression and anxiety due to their minimal side-effects", "keywords": [{"text": "minimal side-effects"}, {"text": "treat depression"}, {"text": "anxiety"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The other antidepressant products", "keywords": [{"text": "antidepressant products"}]}, "sentence": " The other antidepressant products analyzed in the report are tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " North America to retain the largest market share through 2023", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "retain", "tense": "future"}, "text": "to retain", "normalized": "to retain"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "object": {"text": "for the largest share", "keywords": [{"text": "largest share"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "Asia-Pacific region", "keywords": [{"text": "Asia-Pacific region"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "object": {"text": "the fastest CAGR of 4.0%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "4.0"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "is expected to portray", "normalized": "be expect to portray"}}, {"subject": {"text": "The other regions", "keywords": [{"text": "regions"}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "Europe and Latin America , Middle East and Africa (LAMEA)", "keywords": [{"text": "Latin America"}, {"text": "Middle East"}, {"text": "Europe"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "object": {"text": "The other regions analyzed in the report", "keywords": [{"text": "regions"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol Myers Squibb"}, {"text": "Allergan Plc"}, {"text": "Teva Pharmaceutical Industries"}, {"text": "GlaxoSmithKline Plc"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "GlaxoSmithKline Plc", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co.", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Allergan Plc"}, {"text": "H. Lundbeck"}, {"text": "Bristol Myers"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market", "keywords": [{"text": "players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Knowledge tree", "keywords": [{"text": "Knowledge tree"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "a cloud-based intelligence platform that offers more than 2,000 selective", "keywords": [{"text": "cloud-based intelligence platform"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cloud-based intelligence platform", "keywords": [{"text": "cloud-based intelligence platform"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "more than 2,000 selective, off-the-shelf reports on niche markets", "keywords": [{"text": "off-the-shelf reports"}, {"text": "niche markets"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "our clients", "keywords": [{"text": "clients"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "deep insights on the latest trends, dynamic technologies, and emerging application areas", "keywords": [{"text": "deep insights"}, {"text": "latest trends"}, {"text": "dynamic technologies"}, {"text": "application areas"}]}, "action": {"verb": {"text": "gain", "tense": "present"}, "text": "gain", "normalized": "gain"}}, {"subject": {"text": "Purchase", "keywords": [{"text": "Purchase"}]}, "sentence": " Purchase an enterprise user license and get 1 month complimentary access to our Knowledge Tree subscription.", "object": {"text": "complimentary access to our Knowledge Tree subscription", "keywords": [{"text": "complimentary access"}, {"text": "Knowledge Tree subscription"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.942314, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Tricyclic antidepressant", "relevance": 0.591749, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Serotonin", "relevance": 0.569629, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Sertraline", "relevance": 0.510711, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Antidepressant", "relevance": 0.502557, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Venlafaxine", "relevance": 0.427331, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Paroxetine", "relevance": 0.425256, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Escitalopram", "relevance": 0.391406, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Fluoxetine", "relevance": 0.374477, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Generalized anxiety disorder", "relevance": 0.338886, "dbpedia_resource": "http://dbpedia.org/resource/Generalized_anxiety_disorder"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.332167, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}, {"text": "Panic disorder", "relevance": 0.326103, "dbpedia_resource": "http://dbpedia.org/resource/Panic_disorder"}, {"text": "Bupropion", "relevance": 0.316147, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Citalopram", "relevance": 0.313454, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Major depressive disorder", "relevance": 0.311893, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Cognitive behavioral therapy", "relevance": 0.298056, "dbpedia_resource": "http://dbpedia.org/resource/Cognitive_behavioral_therapy"}, {"text": "Anxiety disorder", "relevance": 0.296928, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorder"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.292442, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Bipolar disorder", "relevance": 0.29227, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Imipramine", "relevance": 0.285225, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Social anxiety disorder", "relevance": 0.271796, "dbpedia_resource": "http://dbpedia.org/resource/Social_anxiety_disorder"}, {"text": "Fluvoxamine", "relevance": 0.255876, "dbpedia_resource": "http://dbpedia.org/resource/Fluvoxamine"}, {"text": "Buspirone", "relevance": 0.243854, "dbpedia_resource": "http://dbpedia.org/resource/Buspirone"}, {"text": "Anxiety disorders", "relevance": 0.240146, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorders"}, {"text": "Tranylcypromine", "relevance": 0.233172, "dbpedia_resource": "http://dbpedia.org/resource/Tranylcypromine"}, {"text": "Serotonin syndrome", "relevance": 0.231194, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin_syndrome"}, {"text": "Antidepressants", "relevance": 0.231155, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressants"}, {"text": "Norepinephrine", "relevance": 0.218592, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine"}, {"text": "Mood disorder", "relevance": 0.216627, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Phenelzine", "relevance": 0.206946, "dbpedia_resource": "http://dbpedia.org/resource/Phenelzine"}, {"text": "Monoamine oxidase", "relevance": 0.201872, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.201219, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Dysthymia", "relevance": 0.199306, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Neurotic, stress-related and somatoform disorders", "relevance": 0.19848, "dbpedia_resource": "http://dbpedia.org/resource/Neurotic,_stress-related_and_somatoform_disorders"}, {"text": "Tricyclic", "relevance": 0.193039, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic"}, {"text": "Insomnia", "relevance": 0.187947, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Bristol-Myers Squibb", "relevance": 0.184751, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Alprazolam", "relevance": 0.183882, "dbpedia_resource": "http://dbpedia.org/resource/Alprazolam"}, {"text": "Reuptake inhibitor", "relevance": 0.182119, "dbpedia_resource": "http://dbpedia.org/resource/Reuptake_inhibitor"}, {"text": "Trimipramine", "relevance": 0.181116, "dbpedia_resource": "http://dbpedia.org/resource/Trimipramine"}, {"text": "Suicide", "relevance": 0.181107, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Primary care", "relevance": 0.180741, "dbpedia_resource": "http://dbpedia.org/resource/Primary_care"}, {"text": "Abnormal psychology", "relevance": 0.179316, "dbpedia_resource": "http://dbpedia.org/resource/Abnormal_psychology"}, {"text": "Anxiety", "relevance": 0.174303, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety"}, {"text": "Depression", "relevance": 0.169636, "dbpedia_resource": "http://dbpedia.org/resource/Depression_(mood)"}], "categories": [{"score": 0.997109, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}, {"score": 0.990049, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.921665, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}], "relations": [{"type": "locatedAt", "sentence": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.950179, "arguments": [{"text": "PORTLAND", "location": [0, 8], "entities": [{"type": "GeopoliticalEntity", "text": "PORTLAND"}]}, {"text": "Oregon", "location": [10, 16], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "hasAttribute", "sentence": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.805375, "arguments": [{"text": "patients", "location": [79, 87], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "depression", "location": [103, 113], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.837031, "arguments": [{"text": "Antagonist", "location": [665, 675], "entities": [{"type": "Person", "text": "Antagonist"}]}, {"text": "Others", "location": [705, 711], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "partOfMany", "sentence": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.848678, "arguments": [{"text": "Reuptake Inhibitors", "location": [680, 699], "entities": [{"type": "Person", "text": "Reuptake Inhibitors"}]}, {"text": "Others", "location": [705, 711], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "hasAttribute", "sentence": "(Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg ) Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "score": 0.786356, "arguments": [{"text": "population", "location": [1351, 1361], "entities": [{"type": "Person", "text": "population"}]}, {"text": "depression", "location": [1321, 1331], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "score": 0.978264, "arguments": [{"text": "majority", "location": [2363, 2371], "entities": [{"type": "Cardinal", "text": "majority"}]}, {"text": "patients", "location": [2379, 2387], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "residesIn", "sentence": "For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2593 North America to retain the largest market share through 2023 North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "score": 0.77241, "arguments": [{"text": "population", "location": [3470, 3480], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3488, 3494], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "residesIn", "sentence": "However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "score": 0.571592, "arguments": [{"text": "population", "location": [3714, 3724], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3667, 3673], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "employedBy", "sentence": "Torchbearers of the market The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "score": 0.657339, "arguments": [{"text": "clients", "location": [4426, 4433], "entities": [{"type": "Person", "text": "players"}]}, {"text": "our", "location": [4422, 4425], "entities": [{"type": "Organization", "text": "Asia-Pacific region"}]}]}], "keywords": [{"text": "Depressive Disorder", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.72033, "count": 1}, {"text": "Selective Serotonin Reuptake Inhibitors", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.704178, "count": 1}, {"text": "growth of the antidepressant drugs market", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.684254, "count": 1}, {"text": "Major Depressive Disorder", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.628768, "count": 1}, {"text": "Obsessive-Compulsive Disorder", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.606384, "count": 1}, {"text": "Market Research", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.596894, "count": 1}, {"text": "report", "sentiment": {"score": -0.641951, "label": "negative"}, "relevance": 0.579873, "count": 6}, {"text": "Purchase Enquiry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578398, "count": 1}, {"text": "emergence of novel drug s", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.578174, "count": 1}, {"text": "Generalized Anxiety Disorder", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.576055, "count": 1}, {"text": "Access KNOWLEDGE TREE", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.569671, "count": 1}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.568976, "count": 1}, {"text": "Serotonin-Norepinephrine Reuptake Inhibitors", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.566776, "count": 1}, {"text": "report offers", "sentiment": {"score": -0.437462, "label": "negative"}, "relevance": 0.565039, "count": 1}, {"text": "total revenue", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.564177, "count": 1}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561891, "count": 1}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.559983, "count": 1}, {"text": "Selective serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559476, "count": 1}, {"text": "Panic Disorder", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.5586, "count": 1}, {"text": "Others", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.555224, "count": 2}, {"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.555223, "count": 1}, {"text": "enterprise user license", "sentiment": {"score": 0.697558, "label": "positive"}, "relevance": 0.554155, "count": 1}, {"text": "compulsive disorder segment", "sentiment": {"score": -0.882245, "label": "negative"}, "relevance": 0.550318, "count": 1}, {"text": "Reuptake Inhibitors", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.547938, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.545911, "count": 1}, {"text": "Global Opportunity Analysis", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.538111, "count": 1}, {"text": "side-effects", "sentiment": {"score": -0.806574, "label": "negative"}, "relevance": 0.537454, "count": 2}, {"text": "others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5369, "count": 2}, {"text": "anxiety", "sentiment": {"score": -0.73303, "label": "negative"}, "relevance": 0.536536, "count": 3}, {"text": "poor efficacy", "sentiment": {"score": -0.747675, "label": "negative"}, "relevance": 0.533986, "count": 1}, {"text": "anxiety disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533018, "count": 1}, {"text": "monoamine oxidase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531499, "count": 1}, {"text": "study period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531024, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529739, "count": 1}, {"text": "largest market share", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.528792, "count": 2}, {"text": "Co.", "sentiment": {"score": 0.543486, "label": "positive"}, "relevance": 0.528455, "count": 2}, {"text": "niche markets", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.528134, "count": 1}, {"text": "panic disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5279, "count": 1}, {"text": "stress", "sentiment": {"score": -0.812042, "label": "negative"}, "relevance": 0.527119, "count": 3}, {"text": "tricyclic antidepressants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526628, "count": 1}, {"text": "number of patients", "sentiment": {"score": -0.841082, "label": "negative"}, "relevance": 0.526462, "count": 2}, {"text": "region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525781, "count": 2}, {"text": "disorder", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.524775, "count": 1}, {"text": "Product", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.524589, "count": 1}, {"text": "latest trends", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.523998, "count": 1}, {"text": "largest share", "sentiment": {"score": -0.750848, "label": "negative"}, "relevance": 0.522305, "count": 1}, {"text": "reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520956, "count": 1}, {"text": "depression", "sentiment": {"score": -0.714545, "label": "negative"}, "relevance": 0.52082, "count": 1}, {"text": "Allergan Plc", "sentiment": {"score": 0.543486, "label": "positive"}, "relevance": 0.520551, "count": 1}, {"text": "obsessive-compulsive disorder segment", "sentiment": {"score": -0.882245, "label": "negative"}, "relevance": 0.520494, "count": 1}]}, "extracted_metadata": {"sha1": "c729316b2ad6051f3679a67b5460661851e2110b", "filename": "1542916645209.zip-c129f1678dcdf8b7fc6505d9035952ea.xml", "file_type": "json"}, "external_links": ["https://www.alliedmarketresearch.com/request-sample/2593", "https://www.alliedmarketresearch.com/purchase-enquiry/2593", "https://www.alliedmarketresearch.com/knowledgetree", "https://www.alliedmarketresearch.com/checkout/394361"], "title": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research Seite 1", "forum_title": "Nachrichten - neueste Nachrichten"}, {"id": "9NbYO-oc8rIk7GNuA0l-p9h4-zogbICFzNpDEqLsqxKieN0wjIoo5BY3ZEy0bvzt", "result_metadata": {"score": 34.63786}, "author": "www.4-traders.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.93119, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998854, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.974908, "count": 1}, {"text": "takeda pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.703586, "count": 1}]}, "crawl_date": "2018-11-23T13:49:38Z", "url": "http://www.4-traders.com/SHIRE-9590198/news/Shire-Form-8-3-takeda-pharmaceutical-27653276/", "host": "4-traders.com", "text": "(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: n/a (e) Date position held/dealing undertaken: For an opening", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00+01:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "UBS Asset Management", "relevance": 0.736229, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.460261, "label": "positive"}, "text": "UBS La Maison de Gestion", "relevance": 0.406063, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UBS AG", "relevance": 0.377034, "type": "Company", "disambiguation": {"subtype": [], "name": "UBS", "dbpedia_resource": "http://dbpedia.org/resource/UBS"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.360447, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.308152, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.278798, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.272403, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mr James Mortimer", "relevance": 0.266527, "type": "Person", "disambiguation": {"subtype": [], "name": "James Mortimer", "dbpedia_resource": "http://dbpedia.org/resource/James_Mortimer"}}, {"count": 1, "sentiment": {"score": 0.389935, "label": "positive"}, "text": "Hong Kong", "relevance": 0.260504, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "BodyOfWater", "Cuisine", "City"], "name": "Hong Kong", "dbpedia_resource": "http://dbpedia.org/resource/Hong_Kong"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.2602, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore) Ltd", "relevance": 0.257734, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Australia) Ltd", "relevance": 0.255494, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.253975, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.244381, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Taiwan) Ltd", "relevance": 0.220407, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK) Ltd", "relevance": 0.217187, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.217187, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.217187, "type": "Quantity"}], "sentiment": {"document": {"score": 0.48597, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state 'N/A'", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation", "keywords": [{"text": "consultation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "UBS", "keywords": [{"text": "UBS"}], "entities": [{"type": "Company", "text": "UBS Asset Management"}]}, "sentence": " UBS Asset Management (Americas) Inc.", "object": {"text": "Management", "keywords": [{"text": "Management"}]}, "action": {"verb": {"text": "Asset", "tense": "present"}, "text": "Asset", "normalized": "Asset"}}, {"subject": {"text": "UBS", "keywords": [{"text": "UBS"}], "entities": [{"type": "Company", "text": "UBS Asset Management"}]}, "sentence": " UBS Asset Management (Taiwan) Ltd", "object": {"text": "Management", "keywords": [{"text": "Management"}]}, "action": {"verb": {"text": "Asset", "tense": "present"}, "text": "Asset", "normalized": "Asset"}}, {"subject": {"text": "Shire plc", "keywords": [{"text": "Shire plc"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 23 November 2018 13:30:04 UTC", "object": {"text": "04 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.964236, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Stock", "relevance": 0.721229, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Call option", "relevance": 0.495037, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.478604, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.454077, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.434886, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Stock market", "relevance": 0.431128, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Put option", "relevance": 0.402979, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Unit type", "relevance": 0.389416, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Bond", "relevance": 0.387742, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.381489, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "UBS AG", "relevance": 0.38104, "dbpedia_resource": "http://dbpedia.org/resource/UBS_AG"}, {"text": "Security", "relevance": 0.37988, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Balance sheet", "relevance": 0.37826, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Option contract", "relevance": 0.35946, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}], "categories": [{"score": 0.928619, "label": "/real estate/buying and selling homes"}, {"score": 0.888364, "label": "/finance/financial news"}, {"score": 0.739752, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "JPY TOTAL PURCHASE 102,300 TOTAL SALE 9,000 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "score": 0.763044, "arguments": [{"text": "i", "location": [3430, 3431], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Writing", "location": [3433, 3440], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.853891, "arguments": [{"text": "UBS La Maison", "location": [5981, 5994], "entities": [{"type": "Organization", "text": "UBS La Maison"}]}, {"text": "Ltd", "location": [5977, 5980], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.347201, "arguments": [{"text": "UBS La Maison", "location": [5981, 5994], "entities": [{"type": "Organization", "text": "UBS La Maison"}]}, {"text": "Shire plc", "location": [6057, 6066], "entities": [{"type": "Organization", "text": "Shire plc\n2", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.892896, "arguments": [{"text": "Shire plc", "location": [6057, 6066], "entities": [{"type": "Organization", "text": "Shire plc\n2", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [6067, 6076], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.584019, "arguments": [{"text": "November 2018", "location": [6096, 6109], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [6067, 6076], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4404, 4410], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4421, 4428], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 23/11/2018 Contact name: Mr James Mortimer Telephone number: +44 20 7901 5828 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5302, 5308], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5316, 5320], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5463, 5487], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5455, 5460], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5630, 5635], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5649, 5676], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.759194, "arguments": [{"text": "UBS Asset Management", "location": [5839, 5859], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Ltd", "location": [5835, 5838], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.706849, "arguments": [{"text": "UBS Asset Management", "location": [5917, 5937], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Ltd", "location": [5913, 5916], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.652445, "arguments": [{"text": "UBS Asset Management", "location": [5951, 5971], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Ltd", "location": [5947, 5950], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.448075, "arguments": [{"text": "UBS Asset Management", "location": [5839, 5859], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Hong Kong", "location": [5861, 5870], "entities": [{"type": "GeopoliticalEntity", "text": "Hong Kong"}]}]}, {"type": "locatedAt", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.510206, "arguments": [{"text": "UBS Asset Management", "location": [5880, 5900], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Singapore", "location": [5902, 5911], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 23 November 2018 and is solely responsible for the information contained herein.", "score": 0.534413, "arguments": [{"text": "UBS Asset Management", "location": [5917, 5937], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Taiwan", "location": [5939, 5945], "entities": [{"type": "GeopoliticalEntity", "text": "Taiwan", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "UBS Asset Management", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.918162, "count": 3}, {"text": "UBS AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.849292, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.670347, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.655715, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.640617, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.605891, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.562108, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.560417, "count": 3}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.559549, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.556707, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554401, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.548511, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543216, "count": 1}, {"text": "Code", "sentiment": {"score": -0.329166, "mixed": "1", "label": "negative"}, "relevance": 0.540962, "count": 3}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.538985, "count": 2}, {"text": "short positions", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.538828, "count": 3}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.53797, "count": 3}, {"text": "options", "sentiment": {"score": 0.380708, "mixed": "1", "label": "positive"}, "relevance": 0.537037, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.535381, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.535381, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.53505, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.53499, "count": 2}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.52957, "count": 2}, {"text": "Takeover Panel", "sentiment": {"score": -0.57699, "label": "negative"}, "relevance": 0.529546, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.52934, "count": 1}, {"text": "Cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528714, "count": 2}, {"text": "Owner", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.528542, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.526749, "count": 4}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525411, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.525313, "count": 3}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525255, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.524625, "count": 1}, {"text": "Stock", "sentiment": {"score": -0.737533, "label": "negative"}, "relevance": 0.524404, "count": 2}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524079, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.523348, "count": 2}, {"text": "Rule", "sentiment": {"score": -0.57699, "label": "negative"}, "relevance": 0.522514, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522271, "count": 2}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52205, "count": 1}, {"text": "Shire plc", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.521957, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52175, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.52175, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.521473, "count": 3}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521406, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.833455, "label": "positive"}, "relevance": 0.520221, "count": 1}, {"text": "person", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.519522, "count": 4}, {"text": "INFORMATION", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.51938, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.519044, "count": 1}, {"text": "relation", "sentiment": {"score": 0.370218, "mixed": "1", "label": "positive"}, "relevance": 0.518371, "count": 3}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.517842, "count": 2}, {"text": "Hong Kong", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517785, "count": 1}]}, "extracted_metadata": {"sha1": "8e03715b805ee2d1b144c07167a9a8dc8ec608c4", "filename": "1542980978003.zip-e650d9b66e02029d6cac028f315d02c2.xml", "file_type": "json"}, "external_links": ["http://otp.investis.com/clients/uk/shire/rns1/regulatory-story.aspx?cid=1027&newsid=1209601", "http://www.publicnow.com/view/5512A8C423845E9E52F18F46D8B93EDE0BAECFD2"], "title": "Shire : Form 8.3 - takeda pharmaceutical", "forum_title": "Markets : News - Marketscreener.com"}, {"id": "Sp3aDgvyb7xFcDsyl0ahOqJ_vZqJo14y3m7UMzbJ4jhORjIY5xKlM3GnOU99Q40R", "result_metadata": {"score": 33.708916}, "author": "markets.ft.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.935459, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "RI", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.892905, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858826, "count": 1}, {"text": "EPT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.365719, "count": 1}]}, "crawl_date": "2018-11-23T11:21:04Z", "url": "https://markets.ft.com/data/announce/detail?dockey=1323-13878511-0UK33OG2U6FNTRO8ONBAH5SG8B", "host": "markets.ft.com", "text": "Morgan Securities Plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (c) Name of the party to the offer with which exempt principal trader is connected: Joint Financial Adviser to Takeda Pharmaceutical Company Limited", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T10:02:00-06:00", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.609667, "label": "positive"}, "text": "PRINCIPAL", "relevance": 0.915673, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPMorgan Securities Plc", "relevance": 0.752146, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J.P. Morgan Securities Plc", "relevance": 0.730599, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.622534, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.540647, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Joint Financial Adviser", "relevance": 0.473533, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alwyn Basch", "relevance": 0.446101, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.404438, "type": "JobTitle"}], "sentiment": {"document": {"score": 0.261451, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC", "keywords": [{"text": "PUBLIC"}]}, "sentence": " PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY", "object": {"text": "DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY", "keywords": [{"text": "EXEMPT PRINCIPAL TRADER"}, {"text": "INTERMEDIARY STATUS"}, {"text": "CLIENT-SERVING CAPACITY"}, {"text": "DISCLOSURE"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "action": {"verb": {"text": "DEALING", "tense": "present"}, "text": "DEALING", "normalized": "DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "(e) In addition to the company in 1(b) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?", "object": {"text": "the exempt principal trader making disclosures in respect of any other party to this offer", "keywords": [{"text": "exempt principal trader"}, {"text": "disclosures"}, {"text": "respect"}, {"text": "party"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\"", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "formal or informal, relating to relevant securities", "keywords": [{"text": "relevant securities"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer", "keywords": [{"text": "exempt principal trader"}, {"text": "disclosure"}, {"text": "person"}, {"text": "party"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "action": {"verb": {"text": "refrain", "tense": "present"}, "text": "to deal or refrain", "normalized": "to deal or refrain"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "principal trader", "keywords": [{"text": "principal trader"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:", "object": {"text": "the disclosure and any other person relating to", "keywords": [{"text": "disclosure"}, {"text": "person"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation", "keywords": [{"text": "consultation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk .FERFEUSUDFASEIF", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk .FERFEUSUDFASEIF", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}], "concepts": [{"text": "Option", "relevance": 0.970833, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Stock", "relevance": 0.613185, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.584344, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Call option", "relevance": 0.547514, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Stock market", "relevance": 0.494895, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Strike price", "relevance": 0.481532, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Stock exchange", "relevance": 0.409669, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Put option", "relevance": 0.409096, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}], "categories": [{"score": 0.920156, "label": "/real estate/buying and selling homes"}, {"score": 0.905994, "label": "/finance/financial news"}, {"score": 0.841691, "label": "/finance/investing/day trading"}], "relations": [{"type": "employedBy", "sentence": "RNS Number : 3416I JPMorgan Securities Plc 23 November 2018 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the \"Code\") 1.", "score": 0.506164, "arguments": [{"text": "PRINCIPAL TRADER", "location": [117, 133], "entities": [{"type": "Person", "text": "Information Service"}]}, {"text": "RECOGNISED INTERMEDIARY STATUS", "location": [139, 169], "entities": [{"type": "Organization", "text": "RECOGNISED INTERMEDIARY STATUS"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [4525, 4549], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [4517, 4522], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [4692, 4697], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [4711, 4738], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "employedBy", "sentence": "KEY INFORMATION (a) Name of exempt principal trader: J.P. Morgan Securities Plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (c) Name of the party to the offer with which exempt principal trader is connected: Joint Financial Adviser to Takeda Pharmaceutical Company Limited (d) Date dealing undertaken: 22 November 2018 (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?", "score": 0.531239, "arguments": [{"text": "principal trader", "location": [288, 304], "entities": [{"type": "Person", "text": "Information Service"}]}, {"text": "J.P. Morgan Securities Plc", "location": [306, 332], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities Plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "(a) Purchases and sales Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received (JPY) Lowest price per unit paid/received (JPY) Ordinary Shares Purchases Sales 1,512,958 1,511,958 4,304.0000 4,304.0000 4,272.0000 4,272.0000 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (JPY)", "score": 0.695397, "arguments": [{"text": "Price", "location": [1763, 1768], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [1773, 1777], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit (JPY) (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 3.", "score": 0.604938, "arguments": [{"text": "Price", "location": [3202, 3207], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3212, 3216], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "agentOf", "sentence": "Ordinary Shares Equity Swaps Long Short 5,700 100 100 200 6,400 400 47,000 2,800 100 27,200 1,500 400 4,100 200 8,900 100 76,600 400 37,200 700 1,200 2,100 10,000 200 100 400 3,400 100 84,200 4,900 10,300 12,600 1,200 1,600 100 600 76,600 200 35,200 1,100 900 1,000 100 4,266.0000 4,271.9000 4,272.0000 4,275.0000 4,277.7969 4,279.2500 4,280.0830 4,280.6429 4,281.0000 4,282.7427 4,285.6667 4,287.2500 4,288.7561 4,290.5000 4,290.8315 4,291.4635 4,293.2600 4,303.0000 4,304.0000 4,305.0000 4,306.2360 4,307.6191 4,310.0300 4,310.5000 4,314.1117 4,317.0000 4,266.3200 4,281.4281 4,284.7345 4,285.0081 4,286.5193 4,286.5477 4,290.0692 4,291.0075 4,292.0000 4,292.3863 4,293.2600 4,300.5000 4,304.0000 4,304.3658 4,304.4304 4,307.9000 4,314.5000 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit (JPY) Type e.g. American,", "score": 0.787391, "arguments": [{"text": "i", "location": [2590, 2591], "entities": [{"type": "Person", "text": "Short"}]}, {"text": "Writing", "location": [2593, 2600], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "partOfMany", "sentence": "Ordinary Shares Equity Swaps Long Short 5,700 100 100 200 6,400 400 47,000 2,800 100 27,200 1,500 400 4,100 200 8,900 100 76,600 400 37,200 700 1,200 2,100 10,000 200 100 400 3,400 100 84,200 4,900 10,300 12,600 1,200 1,600 100 600 76,600 200 35,200 1,100 900 1,000 100 4,266.0000 4,271.9000 4,272.0000 4,275.0000 4,277.7969 4,279.2500 4,280.0830 4,280.6429 4,281.0000 4,282.7427 4,285.6667 4,287.2500 4,288.7561 4,290.5000 4,290.8315 4,291.4635 4,293.2600 4,303.0000 4,304.0000 4,305.0000 4,306.2360 4,307.6191 4,310.0300 4,310.5000 4,314.1117 4,317.0000 4,266.3200 4,281.4281 4,284.7345 4,285.0081 4,286.5193 4,286.5477 4,290.0692 4,291.0075 4,292.0000 4,292.3863 4,293.2600 4,300.5000 4,304.0000 4,304.3658 4,304.4304 4,307.9000 4,314.5000 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit (JPY) Type e.g. American,", "score": 0.446296, "arguments": [{"text": "JPY", "location": [2810, 2813], "entities": [{"type": "Organization", "text": "JPY", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "unit", "location": [2804, 2808], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "partOf", "sentence": "European etc. Expiry date Option money paid/ received per unit (JPY) (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 3.", "score": 0.497441, "arguments": [{"text": "unit", "location": [2893, 2897], "entities": [{"type": "Organization", "text": "unit"}]}, {"text": "JPY", "location": [2899, 2902], "entities": [{"type": "Organization", "text": "JPY", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.361749, "arguments": [{"text": "person", "location": [3593, 3599], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [3610, 3617], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "agentOf", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.248856, "arguments": [{"text": "party", "location": [3625, 3630], "entities": [{"type": "Organization", "text": "party", "disambiguation": {"subtype": ["Political"]}}]}, {"text": "concert", "location": [3610, 3617], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "If there are no such agreements, arrangements or understandings, state \"none\" None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \"none\" None Date of disclosure: 23 November 2018 Contact name: Alwyn Basch Telephone number: 020 7742 7407 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [4444, 4450], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [4458, 4462], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}], "keywords": [{"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.724417, "count": 1}, {"text": "PUBLIC DEALING DISCLOSURE", "sentiment": {"score": -0.892033, "label": "negative"}, "relevance": 0.67696, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": -0.892033, "label": "negative"}, "relevance": 0.647199, "count": 1}, {"text": "EXEMPT PRINCIPAL TRADER", "sentiment": {"score": -0.454445, "mixed": "1", "label": "negative"}, "relevance": 0.644924, "count": 2}, {"text": "Name of exempt principal trader", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610175, "count": 1}, {"text": "Code", "sentiment": {"score": -0.608777, "mixed": "1", "label": "negative"}, "relevance": 0.597567, "count": 3}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.595165, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580797, "count": 1}, {"text": "JPMorgan Securities Plc", "sentiment": {"score": -0.892033, "label": "negative"}, "relevance": 0.577738, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.568785, "count": 2}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567414, "count": 1}, {"text": "DEALINGS", "sentiment": {"score": 0.641723, "label": "positive"}, "relevance": 0.56356, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.562463, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560943, "count": 1}, {"text": "offer", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.560085, "count": 4}, {"text": "Financial Adviser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559603, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.554944, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.499053, "label": "positive"}, "relevance": 0.554128, "count": 3}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.641723, "label": "positive"}, "relevance": 0.553355, "count": 1}, {"text": "Rule", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.551733, "count": 1}, {"text": "Highest price", "sentiment": {"score": -0.290538, "label": "negative"}, "relevance": 0.546656, "count": 1}, {"text": "dealings", "sentiment": {"score": 0.752831, "label": "positive"}, "relevance": 0.542501, "count": 2}, {"text": "Lowest price", "sentiment": {"score": -0.290538, "label": "negative"}, "relevance": 0.53968, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.583918, "label": "positive"}, "relevance": 0.539194, "count": 2}, {"text": "arrangements", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.537412, "count": 3}, {"text": "Cash", "sentiment": {"score": -0.290538, "label": "negative"}, "relevance": 0.537016, "count": 1}, {"text": "unit", "sentiment": {"score": 0.484279, "mixed": "1", "label": "positive"}, "relevance": 0.536475, "count": 7}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534202, "count": 1}, {"text": "party", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.53237, "count": 3}, {"text": "option", "sentiment": {"score": 0.621012, "label": "positive"}, "relevance": 0.531809, "count": 3}, {"text": "options", "sentiment": {"score": -0.486327, "mixed": "1", "label": "negative"}, "relevance": 0.531809, "count": 2}, {"text": "understandings", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.530837, "count": 3}, {"text": "relation", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.530082, "count": 2}, {"text": "Name of the party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52714, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52712, "count": 1}, {"text": "consultation", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.526738, "count": 1}, {"text": "indemnity", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.526556, "count": 1}, {"text": "Indemnity", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.526556, "count": 1}, {"text": "Agreements", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.526159, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.526131, "count": 1}, {"text": "Class", "sentiment": {"score": 0.846169, "label": "positive"}, "relevance": 0.525335, "count": 1}, {"text": "J.P. Morgan Securities Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524802, "count": 1}, {"text": "Purchases", "sentiment": {"score": -0.290538, "label": "negative"}, "relevance": 0.522403, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.641723, "label": "positive"}, "relevance": 0.521107, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519877, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.892033, "label": "negative"}, "relevance": 0.519877, "count": 1}, {"text": "arrangement", "sentiment": {"score": 0.307422, "label": "positive"}, "relevance": 0.518732, "count": 1}, {"text": "person", "sentiment": {"score": 0.583918, "label": "positive"}, "relevance": 0.518538, "count": 2}, {"text": "inducement", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.51821, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518044, "count": 1}]}, "extracted_metadata": {"sha1": "6b5108deb6eef408feaedb994d43ca4b6f22ef19", "filename": "1542972064876.zip-399f375a9b0a7d50b6a38df14ff89496.xml", "file_type": "json"}, "external_links": ["http://www.rns.com/"], "title": "Form 8.5 (EPT/RI)- Takeda Pharmaceutical Co Ltd", "forum_title": "Company Announcements \u2013 Latest Company Information \u2013 FT.com"}, {"id": "K7q8F-bWEG4A6hbq9hMzuVySUJb7tHy1-VcHOZwAlpNW1edzaPHIor3HTIdH9pzZ", "result_metadata": {"score": 33.697845}, "author": "Allied Market Research", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgine Corporation", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer HealthCare AG", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.308635, "label": "positive"}, "text": "Amgen", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Penicillin", "relevance": 0.33, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.33, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol Myers Squibb Co", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbot Laboratories", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}], "sentiment": {"document": {"score": 0.942992, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Bristol-Myers Squibb", "relevance": 0.980902, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.90996, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "National Medal of Technology recipients", "relevance": 0.766781, "dbpedia_resource": "http://dbpedia.org/resource/National_Medal_of_Technology_recipients"}, {"text": "New York City", "relevance": 0.752294, "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.745731, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Biogen Idec", "relevance": 0.732325, "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}, {"text": "Eli Lilly and Company", "relevance": 0.682051, "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}], "categories": [{"score": 0.824616, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.667987, "label": "/business and industrial/company"}, {"score": 0.642481, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Penicillin Market", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.891895, "count": 1}, {"text": "New Technology", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.657812, "count": 1}, {"text": "Application", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.650243, "count": 1}, {"text": "Type", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.648378, "count": 1}, {"text": "Customer Segments", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.621592, "count": 1}, {"text": "Biogen IDEC Bayer HealthCare AG", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.618959, "count": 1}, {"text": "Amgen", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.573758, "count": 1}, {"text": "Eli Lilly", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.543833, "count": 1}, {"text": "Celgine Corporation", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.518967, "count": 1}, {"text": "Bristol Myers Squibb Co", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.423384, "count": 1}, {"text": "Top Key Players Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.313974, "count": 1}, {"text": "Abbot Laboratories", "sentiment": {"score": 0.942992, "label": "positive"}, "relevance": 0.300327, "count": 1}]}, "crawl_date": "2018-11-23T14:44:13Z", "url": "https://www.openpr.com/news/1395958/Penicillin-Market-New-Technology-Application-Type-Customer-Segments-and-Top-Key-Players-Takeda-Pharmaceutical-Company-Ltd-Eli-Lilly-Celgine-Corporation-Biogen-IDEC-Bayer-HealthCare-AG-Amgen-Bristol-Myers-Squibb-Co-and-Abbot-Laboratories.html", "host": "openpr.com", "text": "Press release from: Allied Market Research Penicillin is one of the most widely used antibiotic agents derived from Penicillium mold and used against several bacterial infection treatments. Their mechanism of action includes killing the bacteria by bursting their cell wall or by inhibiting their growth. Various kinds of penicillin are", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T14:40:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.367449, "label": "negative"}, "text": "Penicillin", "relevance": 0.961783, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "The market", "relevance": 0.443632, "type": "Company", "disambiguation": {"subtype": [], "name": "The Market", "dbpedia_resource": "http://dbpedia.org/resource/The_Market"}}, {"count": 1, "sentiment": {"score": -0.367723, "label": "negative"}, "text": "mechanism of action", "relevance": 0.310124, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.290983, "label": "negative"}, "text": "Penicillium", "relevance": 0.294721, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.425321, "label": "positive"}, "text": "product development", "relevance": 0.266398, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.662608, "label": "negative"}, "text": "meningitis", "relevance": 0.25448, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.25448, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.415413, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "the most widely used antibiotic agents", "keywords": [{"text": "antibiotic agents"}]}, "sentence": "Press release from: Allied Market Research Penicillin is one of the most widely used antibiotic agents derived from Penicillium mold and used against several bacterial infection treatments.", "object": {"text": "from Penicillium mold", "keywords": [{"text": "Penicillium mold"}], "entities": [{"type": "Company", "text": "Penicillium"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "killing the bacteria by bursting their cell wall or by inhibiting their growth", "keywords": [{"text": "cell wall"}, {"text": "bacteria"}, {"text": "growth"}]}, "sentence": " Their mechanism of action includes killing the bacteria by bursting their cell wall or by inhibiting their growth.", "object": {"text": "Their mechanism of action", "keywords": [{"text": "mechanism"}, {"text": "action"}], "entities": [{"type": "HealthCondition", "text": "mechanism of action"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Various kinds of penicillin", "keywords": [{"text": "Various kinds"}, {"text": "penicillin"}], "entities": [{"type": "Drug", "text": "Penicillin"}]}, "sentence": " Various kinds of penicillin are available to treat different kinds of infections, each one is specific for one kind of bacteria.", "object": {"text": "available"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "each one"}, "sentence": " Various kinds of penicillin are available to treat different kinds of infections, each one is specific for one kind of bacteria.", "object": {"text": "specific for one kind of bacteria", "keywords": [{"text": "bacteria"}, {"text": "kind"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Penicillin drugs", "keywords": [{"text": "Penicillin drugs"}], "entities": [{"type": "Drug", "text": "Penicillin"}]}, "sentence": " Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis, and others.Increase in prevalence of contagious diseases and rise in investments for R&D are the key factors that drive the growth of the global penicillin market.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "are used", "normalized": "be use"}}, {"subject": {"text": "Penicillin drugs", "keywords": [{"text": "Penicillin drugs"}], "entities": [{"type": "Drug", "text": "Penicillin"}]}, "sentence": " Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis, and others.Increase in prevalence of contagious diseases and rise in investments for R&D are the key factors that drive the growth of the global penicillin market.", "object": {"text": "in investments", "keywords": [{"text": "investments"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "the key factors", "keywords": [{"text": "key factors"}]}, "sentence": " Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis, and others.Increase in prevalence of contagious diseases and rise in investments for R&D are the key factors that drive the growth of the global penicillin market.", "object": {"text": "the growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "demand for generic drugs", "keywords": [{"text": "generic drugs"}, {"text": "demand"}]}, "sentence": " In addition, upsurge in demand for generic drugs is anticipated to fuel the market growth.", "object": {"text": "anticipated to fuel the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "sentence": " In addition, upsurge in demand for generic drugs is anticipated to fuel the market growth.", "object": {"text": "demand for generic drugs", "keywords": [{"text": "generic drugs"}, {"text": "demand"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is anticipated to fuel", "normalized": "be anticipate to fuel"}}, {"subject": {"text": "stringent government regulations", "keywords": [{"text": "stringent government regulations"}]}, "sentence": " However, stringent government regulations to limit the use of antibiotics and patent expiry for these antibiotic manufacturing are major factors that restrain the market growth.", "object": {"text": "the use of antibiotics", "keywords": [{"text": "antibiotics"}]}, "action": {"verb": {"text": "limit", "tense": "future"}, "text": "to limit", "normalized": "to limit"}}, {"subject": {"text": "antibiotics and patent expiry for these antibiotic manufacturing", "keywords": [{"text": "patent expiry"}, {"text": "antibiotic manufacturing"}, {"text": "antibiotics"}]}, "sentence": " However, stringent government regulations to limit the use of antibiotics and patent expiry for these antibiotic manufacturing are major factors that restrain the market growth.", "object": {"text": "major factors", "keywords": [{"text": "major factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "major factors", "keywords": [{"text": "major factors"}]}, "sentence": " However, stringent government regulations to limit the use of antibiotics and patent expiry for these antibiotic manufacturing are major factors that restrain the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "restrain", "tense": "present"}, "text": "restrain", "normalized": "restrain"}}, {"subject": {"text": "new product development and usage of penicillin in cell cultures as a potent antibacterial agent", "keywords": [{"text": "potent antibacterial agent"}, {"text": "new product development"}, {"text": "cell cultures"}, {"text": "penicillin"}], "entities": [{"type": "JobTitle", "text": "product development"}, {"type": "Drug", "text": "Penicillin"}]}, "sentence": " Conversely, new product development and usage of penicillin in cell cultures as a potent antibacterial agent are expected to provide potential opportunities for market expansion.Send Enquiry on this report @", "object": {"text": "potential opportunities for market expansion.Send Enquiry on this report", "keywords": [{"text": "market expansion.Send Enquiry"}, {"text": "potential opportunities"}, {"text": "report"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "are expected to provide", "normalized": "be expect to provide"}}], "concepts": [{"text": "Bacteria", "relevance": 0.982431, "dbpedia_resource": "http://dbpedia.org/resource/Bacteria"}, {"text": "Penicillin", "relevance": 0.831956, "dbpedia_resource": "http://dbpedia.org/resource/Penicillin"}, {"text": "Infection", "relevance": 0.6249, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Antibiotic resistance", "relevance": 0.499025, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotic_resistance"}, {"text": "Infectious disease", "relevance": 0.475508, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Immune system", "relevance": 0.472928, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Antibiotic", "relevance": 0.451923, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotic"}, {"text": "Microorganism", "relevance": 0.439287, "dbpedia_resource": "http://dbpedia.org/resource/Microorganism"}, {"text": "Disease", "relevance": 0.407549, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Penicillium", "relevance": 0.399553, "dbpedia_resource": "http://dbpedia.org/resource/Penicillium"}, {"text": "Antiseptic", "relevance": 0.391629, "dbpedia_resource": "http://dbpedia.org/resource/Antiseptic"}, {"text": "Microbiology", "relevance": 0.368209, "dbpedia_resource": "http://dbpedia.org/resource/Microbiology"}, {"text": "Cell", "relevance": 0.330249, "dbpedia_resource": "http://dbpedia.org/resource/Cell_(biology)"}, {"text": "Virus", "relevance": 0.31861, "dbpedia_resource": "http://dbpedia.org/resource/Virus"}, {"text": "Clostridium difficile", "relevance": 0.318603, "dbpedia_resource": "http://dbpedia.org/resource/Clostridium_difficile"}, {"text": "Fungus", "relevance": 0.310816, "dbpedia_resource": "http://dbpedia.org/resource/Fungus"}, {"text": "Cell wall", "relevance": 0.295091, "dbpedia_resource": "http://dbpedia.org/resource/Cell_wall"}, {"text": "Archaea", "relevance": 0.291741, "dbpedia_resource": "http://dbpedia.org/resource/Archaea"}, {"text": "Medicine", "relevance": 0.251467, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Greek loanwords", "relevance": 0.245856, "dbpedia_resource": "http://dbpedia.org/resource/Greek_loanwords"}, {"text": "Abbas Kiarostami", "relevance": 0.243219, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}, {"text": "Mold", "relevance": 0.241022, "dbpedia_resource": "http://dbpedia.org/resource/Mold"}, {"text": "New product development", "relevance": 0.233737, "dbpedia_resource": "http://dbpedia.org/resource/New_product_development"}, {"text": "Peptidoglycan", "relevance": 0.229825, "dbpedia_resource": "http://dbpedia.org/resource/Peptidoglycan"}, {"text": "Inflammation", "relevance": 0.221991, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Biotechnology", "relevance": 0.214354, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Tuberculosis", "relevance": 0.210298, "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}, {"text": "Alexander Fleming", "relevance": 0.209243, "dbpedia_resource": "http://dbpedia.org/resource/Alexander_Fleming"}, {"text": "Staphylococcus aureus", "relevance": 0.209041, "dbpedia_resource": "http://dbpedia.org/resource/Staphylococcus_aureus"}, {"text": "Antibiotics", "relevance": 0.208547, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotics"}, {"text": "Investment", "relevance": 0.20652, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Pseudomonas aeruginosa", "relevance": 0.204395, "dbpedia_resource": "http://dbpedia.org/resource/Pseudomonas_aeruginosa"}, {"text": "Measles", "relevance": 0.199915, "dbpedia_resource": "http://dbpedia.org/resource/Measles"}, {"text": "Bacterial cell structure", "relevance": 0.197046, "dbpedia_resource": "http://dbpedia.org/resource/Bacterial_cell_structure"}, {"text": "Economic growth", "relevance": 0.196993, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "The Key", "relevance": 0.1958, "dbpedia_resource": "http://dbpedia.org/resource/The_Key_(novel)"}, {"text": "Antiviral drug", "relevance": 0.193352, "dbpedia_resource": "http://dbpedia.org/resource/Antiviral_drug"}, {"text": "Economics", "relevance": 0.190017, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Beta-lactam antibiotic", "relevance": 0.189079, "dbpedia_resource": "http://dbpedia.org/resource/Beta-lactam_antibiotic"}, {"text": "Cell membrane", "relevance": 0.188498, "dbpedia_resource": "http://dbpedia.org/resource/Cell_membrane"}, {"text": "Generic drug", "relevance": 0.18829, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Meningitis", "relevance": 0.18447, "dbpedia_resource": "http://dbpedia.org/resource/Meningitis"}, {"text": "Enzyme", "relevance": 0.184183, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme"}, {"text": "Fever", "relevance": 0.181225, "dbpedia_resource": "http://dbpedia.org/resource/Fever"}, {"text": "Kind", "relevance": 0.180408, "dbpedia_resource": "http://dbpedia.org/resource/Kind"}, {"text": "Gene", "relevance": 0.1787, "dbpedia_resource": "http://dbpedia.org/resource/Gene"}, {"text": "Escherichia coli", "relevance": 0.178655, "dbpedia_resource": "http://dbpedia.org/resource/Escherichia_coli"}, {"text": "Efflux", "relevance": 0.178254, "dbpedia_resource": "http://dbpedia.org/resource/Efflux_(microbiology)"}, {"text": "Selman Waksman", "relevance": 0.178048, "dbpedia_resource": "http://dbpedia.org/resource/Selman_Waksman"}, {"text": "Marketing", "relevance": 0.177949, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}], "categories": [{"score": 0.947668, "label": "/health and fitness/disease"}, {"score": 0.743708, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.674658, "label": "/health and fitness/therapy"}], "relations": [{"type": "partOfMany", "sentence": "Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis, and others.", "score": 0.76014, "arguments": [{"text": "infections", "location": [628, 638], "entities": [{"type": "HealthCondition", "text": "infections"}]}, {"text": "diseases", "location": [604, 612], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "partOfMany", "sentence": "Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis, and others.", "score": 0.492467, "arguments": [{"text": "meningitis", "location": [640, 650], "entities": [{"type": "HealthCondition", "text": "meningitis"}]}, {"text": "diseases", "location": [604, 612], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}], "keywords": [{"text": "Market Research Penicillin", "sentiment": {"score": 0.557458, "label": "positive"}, "relevance": 0.723461, "count": 1}, {"text": "key factors", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.639186, "count": 1}, {"text": "Press release", "sentiment": {"score": 0.557458, "label": "positive"}, "relevance": 0.618909, "count": 1}, {"text": "comprehensive analysis of the key developments", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.618412, "count": 1}, {"text": "use of antibiotics", "sentiment": {"score": -0.818876, "label": "negative"}, "relevance": 0.616605, "count": 1}, {"text": "sample copy of this report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613282, "count": 1}, {"text": "antibiotic agents", "sentiment": {"score": 0.557458, "label": "positive"}, "relevance": 0.607179, "count": 1}, {"text": "report", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.587558, "count": 4}, {"text": "antibiotics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580086, "count": 1}, {"text": "depth analysis", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.579205, "count": 1}, {"text": "stringent government regulations", "sentiment": {"score": -0.818876, "label": "negative"}, "relevance": 0.576024, "count": 1}, {"text": "growth of the global penicillin market", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.566411, "count": 1}, {"text": "cell wall", "sentiment": {"score": -0.537902, "label": "negative"}, "relevance": 0.565945, "count": 1}, {"text": "cell cultures", "sentiment": {"score": 0.661093, "label": "positive"}, "relevance": 0.561736, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554025, "count": 1}, {"text": "generic drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553581, "count": 1}, {"text": "Key Benefits", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.546091, "count": 1}, {"text": "Various kinds of penicillin", "sentiment": {"score": -0.851473, "label": "negative"}, "relevance": 0.545729, "count": 1}, {"text": "new product development", "sentiment": {"score": 0.661093, "label": "positive"}, "relevance": 0.539627, "count": 1}, {"text": "major factors", "sentiment": {"score": -0.818876, "label": "negative"}, "relevance": 0.539416, "count": 1}, {"text": "bacterial infection treatments", "sentiment": {"score": 0.557458, "label": "positive"}, "relevance": 0.53187, "count": 1}, {"text": "usage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531155, "count": 1}, {"text": "industry", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.530757, "count": 1}, {"text": "upsurge", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530704, "count": 1}, {"text": "meningitis", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.530431, "count": 1}, {"text": "treatment of diseases", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.529532, "count": 1}, {"text": "others", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.52953, "count": 1}, {"text": "geography", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.528741, "count": 1}, {"text": "sample", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.527918, "count": 1}, {"text": "investments", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.52521, "count": 1}, {"text": "development strategies", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.524107, "count": 1}, {"text": "demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523085, "count": 1}, {"text": "growth", "sentiment": {"score": -0.537902, "label": "negative"}, "relevance": 0.520411, "count": 1}, {"text": "strategic business", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.519908, "count": 1}, {"text": "prevalence of contagious diseases", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.517149, "count": 1}, {"text": "mechanism of action", "sentiment": {"score": -0.537902, "label": "negative"}, "relevance": 0.516963, "count": 1}, {"text": "com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516573, "count": 1}, {"text": "bacteria", "sentiment": {"score": -0.537902, "label": "negative"}, "relevance": 0.516419, "count": 1}, {"text": "diversity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515979, "count": 1}, {"text": "Penicillin drugs", "sentiment": {"score": -0.94812, "label": "negative"}, "relevance": 0.51515, "count": 1}, {"text": "market growth", "sentiment": {"score": -0.818876, "label": "negative"}, "relevance": 0.513111, "count": 2}, {"text": "prevailing opportunities", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.511159, "count": 1}, {"text": "potent antibacterial agent", "sentiment": {"score": 0.661093, "label": "positive"}, "relevance": 0.508645, "count": 1}, {"text": "antimicrobial resistance of microbes", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.507614, "count": 1}, {"text": "competitive scenario of the market", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.502248, "count": 1}, {"text": "key manufacturers", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.500758, "count": 1}, {"text": "regional market", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.497157, "count": 1}, {"text": "market estimations", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.496865, "count": 1}, {"text": "different kinds of infections", "sentiment": {"score": -0.851473, "label": "negative"}, "relevance": 0.495809, "count": 1}, {"text": "introduction of novel antibiotics", "sentiment": {"score": 0.805309, "label": "positive"}, "relevance": 0.491041, "count": 1}]}, "extracted_metadata": {"sha1": "8ccda577d04b5e1cb1bdccb44f2d7ac0a076d99f", "filename": "1542984253051.zip-17b50f3ad8f091f351389a2c3314600c.xml", "file_type": "json"}, "external_links": ["https://www.alliedmarketresearch.com/request-toc-and-sample/4665?utm_source=Prathm_OPR"], "title": "Penicillin Market : New Technology, Application, Type, Customer Segments, and Top Key Players Takeda Pharmaceutical Company Ltd., Eli Lilly , Celgine Corporation, Biogen IDEC Bayer HealthCare AG ,Amgen, Bristol Myers Squibb Co and Abbot Laboratories", "forum_title": "openPR.com - Newsfeed"}, {"id": "mI75zAsWfoJO3mpBWCnjSnQuAFle56T5hu8VstTG4XdyigZPBKkURuj5K6OGcDXR", "result_metadata": {"score": 31.880922}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.904926, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960803, "count": 1}, {"text": "FORM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.769699, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344607, "count": 1}]}, "crawl_date": "2018-11-22T15:05:35Z", "url": "https://www.businesswire.com/news/home/20181122005222/en/BARCLAYS-PLC-UK-Regulatory-Announcement-FORM-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T12:47:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.73853, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.706069, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.573379, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": -0.388499, "label": "negative"}, "text": "Class of Product Nature", "relevance": 0.563757, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.547485, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542691, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.520451, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512267, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.46767, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.451584, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,188,500 1.28%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,303,164 1.42%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,163,786 1.53%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,745,895 1.60%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,875,995 4.26%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,988,550 4.28%", "relevance": 0.451584, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.451584, "type": "Quantity"}], "sentiment": {"document": {"score": 0.637803, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,988,550 4.28% 33,875,995 4.26% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,875,995 4.26"}, {"type": "Quantity", "text": "33,988,550 4.28"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,303,164 1.42% 12,745,895 1.60% (2) Cash-settled derivatives: 12,163,786 1.53% 10,188,500 1.28% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,988,550 4.28% 33,875,995 4.26% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,988,550 4.28% 33,875,995 4.26% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,875,995 4.26"}, {"type": "Quantity", "text": "33,988,550 4.28"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,303,164 1.42% 12,745,895 1.60% (2) Cash-settled derivatives: 12,163,786 1.53% 10,188,500 1.28% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,988,550 4.28% 33,875,995 4.26% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 22 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659818 Time of Receipt (offset from UTC): 20181122T121725+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.970869, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.755568, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.690629, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.604265, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.507913, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.418221, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.410384, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.383848, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.377783, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.345695, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "December", "relevance": 0.323469, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Contract", "relevance": 0.322515, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.321664, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}], "categories": [{"score": 0.85531, "label": "/real estate/buying and selling homes"}, {"score": 0.797723, "label": "/finance/financial news"}, {"score": 0.790833, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 1,900 4,323.3076 JPY Ordinary NPV CFD Long 6,000 4,342.5658 JPY Ordinary NPV SWAP Short 35 4,329.4329 JPY Ordinary NPV SWAP Short 106 4,326.0992 JPY Ordinary NPV SWAP Short 175 4,324.0026 JPY Ordinary NPV SWAP Short 700 4,319.8571 JPY Ordinary NPV SWAP Short 1,404 4,322.6964 JPY Ordinary NPV SWAP Short 1,600 4,323.6923 JPY Ordinary NPV SWAP Short 1,840 4,324.9541 JPY Ordinary NPV SWAP Short 1,900 4,319.0000 JPY Ordinary NPV SWAP Short 4,592 4,322.8711 JPY Ordinary NPV SWAP Short 8,391 4,324.4812 JPY Ordinary NPV SWAP Short 8,553 4,324.4528 JPY Ordinary NPV SWAP Short 14,004 4,327.5501 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing,", "score": 0.682599, "arguments": [{"text": "i", "location": [5988, 5989], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [5991, 5998], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6962, 6968], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6979, 6986], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 22 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7888, 7894], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7902, 7906], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [8334, 8340], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8348, 8361], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7969, 7993], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7961, 7966], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10480, 10504], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10472, 10477], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8128, 8133], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8147, 8174], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10639, 10644], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10658, 10685], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8410, 8416], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8442, 8454], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659818 Time of Receipt (offset from UTC): 20181122T121725+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10785, 10788], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10764, 10771], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.751277, "count": 1}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.871968, "label": "positive"}, "relevance": 0.677181, "count": 19}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.871968, "label": "positive"}, "relevance": 0.64644, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.643948, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.630129, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.64284, "label": "positive"}, "relevance": 0.617983, "count": 4}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.612361, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0.871968, "label": "positive"}, "relevance": 0.591223, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.577788, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.576315, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.584183, "label": "positive"}, "relevance": 0.574561, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573547, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.570997, "count": 2}, {"text": "options", "sentiment": {"score": 0.723906, "label": "positive"}, "relevance": 0.567974, "count": 4}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.871968, "label": "positive"}, "relevance": 0.565159, "count": 1}, {"text": "relevant Purchase", "sentiment": {"score": 0.871968, "label": "positive"}, "relevance": 0.557634, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556511, "count": 1}, {"text": "Code", "sentiment": {"score": -0.29311, "mixed": "1", "label": "negative"}, "relevance": 0.554392, "count": 5}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.551916, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.543097, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540181, "count": 2}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.539851, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.539515, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.535994, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.532639, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.532639, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532158, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.531969, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.53149, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.530946, "count": 1}, {"text": "positions", "sentiment": {"score": 0.806498, "label": "positive"}, "relevance": 0.530324, "count": 2}, {"text": "relation", "sentiment": {"score": 0.664279, "label": "positive"}, "relevance": 0.530048, "count": 5}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529831, "count": 1}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527845, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526374, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525305, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524241, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.52424, "count": 8}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.524127, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.524127, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.524019, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523932, "count": 2}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523631, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.52347, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522904, "count": 3}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522859, "count": 1}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.522783, "count": 4}, {"text": "sale Number of Price", "sentiment": {"score": 0.871968, "label": "positive"}, "relevance": 0.522187, "count": 1}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.52083, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.520646, "count": 3}]}, "extracted_metadata": {"sha1": "8d2467b82c3c3ae7aadd8c44deb8445cc19403a9", "filename": "1542899135591.zip-becbfca837a2c276c167dde6d5deef1d.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: FORM 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "NQ-QYFKbM-Uo2rLOz68zAF-5-0va23HFr9xm7VbYLOPbhqFuL_ZKtibl-oRzRrrw", "result_metadata": {"score": 30.908422}, "author": "admin", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.901665, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.998349, "label": "/science/medicine"}], "relations": [{"type": "partOf", "sentence": "Precision Medicine Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2017-2022", "score": 0.568454, "arguments": [{"text": "Growing Healthcare Sector", "location": [59, 84], "entities": [{"type": "Organization", "text": "Growing Healthcare Sector"}]}, {"text": "Precision Medicine Market Profound Impact on the Market", "location": [0, 55], "entities": [{"type": "Organization", "text": "Precision Medicine Market Profound Impact on the Market"}]}]}], "keywords": [{"text": "Precision Medicine Market Profound Impact", "sentiment": {"score": 0.901665, "label": "positive"}, "relevance": 0.996643, "count": 1}, {"text": "Market", "sentiment": {"score": 0.901665, "label": "positive"}, "relevance": 0.925045, "count": 1}, {"text": "Healthcare Sector", "sentiment": {"score": 0.901665, "label": "positive"}, "relevance": 0.163669, "count": 1}, {"text": "Forecast Period", "sentiment": {"score": 0.901665, "label": "positive"}, "relevance": 0.080625, "count": 1}]}, "crawl_date": "2018-11-23T14:14:07Z", "url": "http://www.abnewswire.com/pressreleases/precision-medicine-market-profound-impact-on-the-market-by-growing-healthcare-sector-during-the-forecast-period-20172022_294595.html", "host": "abnewswire.com", "text": "Key Players for Global Precision Medicine Market: Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biom\u00e9rieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T12:26:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.517989, "label": "positive"}, "text": "Global Precision Medicine", "relevance": 0.924936, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0.621704, "label": "positive"}, "text": "Precision For Medicine", "relevance": 0.382047, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cetics Healthcare Technologies Gmbh", "relevance": 0.184181, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.178976, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ge Healthcare", "relevance": 0.177268, "type": "Company", "disambiguation": {"subtype": [], "name": "GE Healthcare", "dbpedia_resource": "http://dbpedia.org/resource/GE_Healthcare"}}, {"count": 2, "sentiment": {"score": 0.552715, "label": "positive"}, "text": "Europe", "relevance": 0.176374, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laboratory Corporation Of America Holdings", "relevance": 0.175589, "type": "Company", "disambiguation": {"subtype": [], "name": "LabCorp", "dbpedia_resource": "http://dbpedia.org/resource/LabCorp"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.169361, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 2, "sentiment": {"score": 0.433287, "label": "positive"}, "text": "America", "relevance": 0.168944, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.167602, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biobase Gmbh", "relevance": 0.165962, "type": "Company", "disambiguation": {"subtype": [], "name": "BIOBASE (company)", "dbpedia_resource": "http://dbpedia.org/resource/BIOBASE_(company)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Caris Life Sciences", "relevance": 0.165111, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.159021, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0.467758, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.158694, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glaxosmithkline Plc", "relevance": 0.151632, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Molecular Health Gmbh", "relevance": 0.150209, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Intel Corporation", "relevance": 0.148335, "type": "Company", "disambiguation": {"subtype": ["OperatingSystemDeveloper", "ProcessorManufacturer", "SoftwareDeveloper"], "name": "Intel", "dbpedia_resource": "http://dbpedia.org/resource/Intel"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medtronic", "relevance": 0.14721, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Medtronic", "dbpedia_resource": "http://dbpedia.org/resource/Medtronic"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quest Diagnostics Inc", "relevance": 0.145612, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.144717, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.144639, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Pharma", "relevance": 0.142491, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.443877, "label": "negative"}, "text": "Biom\u00e9rieux Sa", "relevance": 0.141044, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Healthcore, Inc.", "relevance": 0.140279, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Randox Laboratories Ltd.", "relevance": 0.139937, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ibm", "relevance": 0.137806, "type": "Company", "disambiguation": {"subtype": ["SoftwareLicense", "OperatingSystemDeveloper", "ProcessorManufacturer", "SoftwareDeveloper", "CompanyFounder", "ProgrammingLanguageDesigner", "ProgrammingLanguageDeveloper"], "name": "IBM", "dbpedia_resource": "http://dbpedia.org/resource/IBM"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cepheid Inc.", "relevance": 0.135911, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Almac Group, Ltd.", "relevance": 0.135795, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asuragen, Inc.", "relevance": 0.135194, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.135194, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$38.92 billion", "relevance": 0.135194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$88.64 billion", "relevance": 0.135194, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12.48%", "relevance": 0.135194, "type": "Quantity"}], "sentiment": {"document": {"score": 0.541894, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "2018 This study", "keywords": [{"text": "study"}]}, "sentence": "Friday - November 23, 2018 Precision Medicine Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2017-2022 Posted on November 23, 2018 This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Precision Medicine Market over the forecast period.", "object": {"text": "the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Precision Medicine Market over the forecast period", "keywords": [{"text": "current market scenario"}, {"text": "Global Precision Medicine"}, {"text": "forecast period"}, {"text": "market dynamics"}], "entities": [{"type": "PrintMedia", "text": "Global Precision Medicine"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "an individual\u2019s genetic profile", "keywords": [{"text": "genetic profile"}]}, "sentence": " Precision medicine refers to medicines developed as per an individual\u2019s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases.", "object": {"text": "as a guide for the prevention, diagnosis and treatment of diseases", "keywords": [{"text": "guide"}, {"text": "prevention"}, {"text": "diagnosis"}, {"text": "treatment"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "The global precision medicine market", "keywords": [{"text": "global precision medicine"}, {"text": "market"}]}, "sentence": " The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022.", "object": {"text": "valued at $38.92 billion in 2015", "entities": [{"type": "Quantity", "text": "$38.92 billion"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The global precision medicine market", "keywords": [{"text": "global precision medicine"}, {"text": "market"}]}, "sentence": " The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022.", "object": {"text": "at $38.92 billion in 2015", "entities": [{"type": "Quantity", "text": "$38.92 billion"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "was valued", "normalized": "be value"}}, {"subject": {"text": "The global precision medicine market", "keywords": [{"text": "global precision medicine"}, {"text": "market"}]}, "sentence": " The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022.", "object": {"text": "$88.64 billion by 2022", "entities": [{"type": "Quantity", "text": "$88.64 billion"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2022.", "object": {"text": "a growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "perform", "tense": "future"}, "text": "is expected to perform", "normalized": "be expect to perform"}}, {"subject": {"text": "The major market driving factor for precision medicine", "keywords": [{"text": "market driving factor"}, {"text": "precision medicine"}]}, "sentence": " The major market driving factor for precision medicine are patient\u2019s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.", "object": {"text": "patient\u2019s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others", "keywords": [{"text": "portable healthcare devices"}, {"text": "UV rays"}, {"text": "patient\u2019s involvement"}, {"text": "wireless technologies"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Sample Copy", "keywords": [{"text": "Sample Copy"}]}, "sentence": " Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/925", "object": {"text": "@ https://www.marketresearchfuture.com/sample_request/925", "keywords": [{"text": "https://www.marketresearchfuture.com/sample_request/925"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "Get", "tense": "present"}, "text": "Get", "normalized": "Get"}}, {"subject": {"text": "potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application", "keywords": [{"text": "high diagnostic cost"}, {"text": "stringent regulations"}, {"text": "reimbursement policies"}, {"text": "potential threat"}]}, "sentence": " The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.", "object": {"text": "The market constraints", "keywords": [{"text": "market constraints"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa,", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Teva Pharmaceutical Industries"}, {"text": "Sanofi Pharma"}, {"text": "Randox Laboratories"}], "entities": [{"type": "Company", "text": "Randox Laboratories Ltd."}, {"type": "Company", "text": "Sanofi Pharma"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}]}, "sentence": " Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biom\u00e9rieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine", "object": {"text": "Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine", "keywords": [{"text": "Molecular Health Gmbh"}, {"text": "Intel Corporation"}, {"text": "Life Sciences"}, {"text": "Healthcore"}], "entities": [{"type": "Company", "text": "Healthcore, Inc."}, {"type": "Company", "text": "Ibm", "disambiguation": {"subtype": ["SoftwareLicense", "Organization", "OperatingSystemDeveloper", "ProcessorManufacturer", "SoftwareDeveloper", "CompanyFounder", "ProgrammingLanguageDesigner", "ProgrammingLanguageDeveloper"], "name": "IBM", "dbpedia_resource": "http://dbpedia.org/resource/IBM"}}, {"type": "Company", "text": "Intel Corporation", "disambiguation": {"subtype": ["OperatingSystemDeveloper", "ProcessorManufacturer", "SoftwareDeveloper"], "name": "Intel", "dbpedia_resource": "http://dbpedia.org/resource/Intel"}}, {"type": "Company", "text": "Molecular Health Gmbh"}, {"type": "PrintMedia", "text": "Precision For Medicine"}]}, "action": {"verb": {"text": "Caris", "tense": "present"}, "text": "Caris", "normalized": "Caris"}}, {"subject": {"text": "Global Precision Medicine market", "keywords": [{"text": "Global Precision Medicine"}, {"text": "market"}], "entities": [{"type": "PrintMedia", "text": "Global Precision Medicine"}]}, "sentence": " Segments: Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.", "object": {"text": "been segmented on the basis of ecosystem, sub-market, therapeutics and region", "keywords": [{"text": "therapeutics"}, {"text": "ecosystem"}, {"text": "basis"}, {"text": "sub-market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Global Precision Medicine market", "keywords": [{"text": "Global Precision Medicine"}, {"text": "market"}], "entities": [{"type": "PrintMedia", "text": "Global Precision Medicine"}]}, "sentence": " Segments: Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.", "object": {"text": "segmented on the basis of ecosystem, sub-market, therapeutics and region", "keywords": [{"text": "therapeutics"}, {"text": "ecosystem"}, {"text": "basis"}, {"text": "sub-market"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Global Precision Medicine market", "keywords": [{"text": "Global Precision Medicine"}, {"text": "market"}], "entities": [{"type": "PrintMedia", "text": "Global Precision Medicine"}]}, "sentence": " Segments: Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.", "object": {"text": "on the basis of ecosystem, sub-market, therapeutics and region", "keywords": [{"text": "therapeutics"}, {"text": "ecosystem"}, {"text": "basis"}, {"text": "sub-market"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Regional Analysis Globally North America", "keywords": [{"text": "Regional Analysis"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Regional Analysis Globally North America is the largest market for global precision medicine.", "object": {"text": "the largest market for global precision medicine", "keywords": [{"text": "global precision medicine"}, {"text": "largest market"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe is the second-largest market for global precision medicine.", "object": {"text": "the second-largest market for global precision medicine", "keywords": [{"text": "second-largest market"}, {"text": "global precision medicine"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The near future market for precision medicine", "keywords": [{"text": "future market"}, {"text": "precision medicine"}]}, "sentence": " The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only.", "object": {"text": "by the developed regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be dominated", "normalized": "will be dominate"}}, {"subject": {"text": "by the developed regions with developing regions providing a supporting role only", "keywords": [{"text": "regions"}, {"text": "role"}]}, "sentence": " The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only.", "object": {"text": "The near future market for precision medicine", "keywords": [{"text": "future market"}, {"text": "precision medicine"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will be dominated", "normalized": "will be dominate"}}, {"subject": {"text": "the developed regions with developing regions", "keywords": [{"text": "developed regions"}]}, "sentence": " The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only.", "object": {"text": "a supporting role", "keywords": [{"text": "role"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "the developing regions market particularly Asia Pacific", "keywords": [{"text": "regions market"}, {"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.", "object": {"text": "the fastest"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "the developing regions market particularly Asia Pacific", "keywords": [{"text": "regions market"}, {"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.", "object": {"text": "the key to the future", "keywords": [{"text": "key"}, {"text": "future"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "to be", "normalized": "to be"}}], "concepts": [{"text": "Teva Pharmaceutical Industries", "relevance": 0.951227, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Medicine", "relevance": 0.838087, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.778981, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "GlaxoSmithKline", "relevance": 0.76934, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Pharmacology", "relevance": 0.718565, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.702611, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Future", "relevance": 0.632112, "dbpedia_resource": "http://dbpedia.org/resource/Future"}, {"text": "Pharmaceutical drug", "relevance": 0.564056, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Health", "relevance": 0.558619, "dbpedia_resource": "http://dbpedia.org/resource/Health"}, {"text": "Health care", "relevance": 0.514514, "dbpedia_resource": "http://dbpedia.org/resource/Health_care"}, {"text": "Generic drug", "relevance": 0.496734, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}], "categories": [{"score": 0.911097, "label": "/science/medicine"}, {"score": 0.751675, "label": "/health and fitness/disease"}, {"score": 0.745847, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "partOf", "sentence": "Friday - November 23, 2018 Precision Medicine Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2017-2022 Posted on November 23, 2018 This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Precision Medicine Market over the forecast period.", "score": 0.50351, "arguments": [{"text": "Growing Healthcare Sector", "location": [86, 111], "entities": [{"type": "Organization", "text": "Growing Healthcare Sector"}]}, {"text": "Precision Medicine Market Profound Impact on the Market", "location": [27, 82], "entities": [{"type": "Organization", "text": "Precision Medicine Market Profound Impact on the Market"}]}]}, {"type": "timeOf", "sentence": "Friday - November 23, 2018 Precision Medicine Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2017-2022 Posted on November 23, 2018 This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Precision Medicine Market over the forecast period.", "score": 0.559385, "arguments": [{"text": "2017-2022", "location": [139, 148], "entities": [{"type": "Date", "text": "2017-2022"}]}, {"text": "Posted", "location": [149, 155], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "timeOf", "sentence": "Friday - November 23, 2018 Precision Medicine Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2017-2022 Posted on November 23, 2018 This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Precision Medicine Market over the forecast period.", "score": 0.830149, "arguments": [{"text": "November 23, 2018", "location": [159, 176], "entities": [{"type": "Date", "text": "November 23, 2018"}]}, {"text": "Posted", "location": [149, 155], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "hasAttribute", "sentence": "The major market driving factor for precision medicine are patient's involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.", "score": 0.654951, "arguments": [{"text": "patient", "location": [842, 849], "entities": [{"type": "Person", "text": "patient"}]}, {"text": "diseases", "location": [983, 991], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "partOf", "sentence": "Key Players for Global Precision Medicine Market: Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biom\u00e9rieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine Segments: Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.", "score": 0.450975, "arguments": [{"text": "Global Precision Medicine Market", "location": [1566, 1598], "entities": [{"type": "Organization", "text": "Global Precision Medicine Market"}]}, {"text": "Key Players", "location": [1550, 1561], "entities": [{"type": "Organization", "text": "Key Players", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.", "score": 0.382432, "arguments": [{"text": "Asia", "location": [2637, 2641], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2642, 2649], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "employedBy", "sentence": "Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925 Detailed Table of Contents: 1.1 Scope Of The Study 1.2 Precision Medicine: Report Coverage 1.3 Research Methodology 1.3.1 Research Methodology For The Global Market Study 1.3.2 Global Precision Medicine: Research Methodology 1.3.3 Key Data Point Sources 1.4 Report Description", "score": 0.6404, "arguments": [{"text": "Scope", "location": [2923, 2928], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Precision Medicine", "location": [2946, 2964], "entities": [{"type": "Organization", "text": "Precision Medicine Market Profound Impact on the Market"}]}]}, {"type": "partOf", "sentence": "Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925 Detailed Table of Contents: 1.1 Scope Of The Study 1.2 Precision Medicine: Report Coverage 1.3 Research Methodology 1.3.1 Research Methodology For The Global Market Study 1.3.2 Global Precision Medicine: Research Methodology 1.3.3 Key Data Point Sources 1.4 Report Description", "score": 0.622279, "arguments": [{"text": "Global Precision Medicine", "location": [3068, 3093], "entities": [{"type": "Organization", "text": "Global Precision Medicine Market"}]}, {"text": "Methodology For The Global Market Study", "location": [3022, 3061], "entities": [{"type": "Organization", "text": "Methodology For The Global Market Study"}]}]}], "keywords": [{"text": "Precision Medicine Market Profound Impact", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.864911, "count": 1}, {"text": "Market", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.684512, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.624157, "count": 1}, {"text": "market dynamics", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.584611, "count": 1}, {"text": "Healthcare Sector", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.584565, "count": 1}, {"text": "potential threat", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.57793, "count": 1}, {"text": "major countries", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.575746, "count": 1}, {"text": "Laboratory Corporation Of America Holdings", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.565595, "count": 1}, {"text": "Regional Analysis Globally North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565486, "count": 1}, {"text": "global precision medicine market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565358, "count": 1}, {"text": "limited knowledge", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.564931, "count": 1}, {"text": "Precision medicine", "sentiment": {"score": 0.417542, "label": "positive"}, "relevance": 0.561034, "count": 1}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55928, "count": 1}, {"text": "medicines", "sentiment": {"score": 0.417542, "label": "positive"}, "relevance": 0.558844, "count": 1}, {"text": "personal data", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.556778, "count": 1}, {"text": "current market scenario", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.555628, "count": 1}, {"text": "major market", "sentiment": {"score": -0.323294, "label": "negative"}, "relevance": 0.554942, "count": 1}, {"text": "Cetics Healthcare Technologies Gmbh", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.552114, "count": 1}, {"text": "Ltd", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.550948, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0.958936, "label": "positive"}, "relevance": 0.550698, "count": 1}, {"text": "market", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.548261, "count": 2}, {"text": "high diagnostic cost", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.546083, "count": 1}, {"text": "Intel Corporation", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.545513, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.544202, "count": 1}, {"text": "personal healthcare", "sentiment": {"score": -0.323294, "label": "negative"}, "relevance": 0.541877, "count": 1}, {"text": "regulatory framework", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.541853, "count": 1}, {"text": "Johnson", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.5371, "count": 2}, {"text": "Research Methodology", "sentiment": {"score": 0.991735, "label": "positive"}, "relevance": 0.531536, "count": 3}, {"text": "region", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.530309, "count": 1}, {"text": "regions", "sentiment": {"score": 0.813143, "label": "positive"}, "relevance": 0.530309, "count": 2}, {"text": "November", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.530258, "count": 2}, {"text": "Precision", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.529795, "count": 1}, {"text": "Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528475, "count": 1}, {"text": "possible applications of precision medicine", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.527735, "count": 1}, {"text": "Randox Laboratories Ltd", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.526377, "count": 1}, {"text": "Biom\u00e9rieux Sa", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.525328, "count": 1}, {"text": "Teva Pharmaceutical Industries Ltd", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.52405, "count": 1}, {"text": "Quest Diagnostics Inc", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.523878, "count": 1}, {"text": "Global Precision Medicine Market", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.522542, "count": 1}, {"text": "Key Players", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.522157, "count": 1}, {"text": "integration of wireless technologies", "sentiment": {"score": -0.323294, "label": "negative"}, "relevance": 0.52146, "count": 1}, {"text": "study", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.521287, "count": 1}, {"text": "trends", "sentiment": {"score": 0.876288, "label": "positive"}, "relevance": 0.520506, "count": 1}, {"text": "Novartis", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.520304, "count": 1}, {"text": "Cepheid Inc.", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.519852, "count": 1}, {"text": "barrier", "sentiment": {"score": -0.913159, "label": "negative"}, "relevance": 0.519536, "count": 1}, {"text": "genetic diseases", "sentiment": {"score": -0.323294, "label": "negative"}, "relevance": 0.519136, "count": 1}, {"text": "Ibm", "sentiment": {"score": -0.627704, "label": "negative"}, "relevance": 0.517599, "count": 1}, {"text": "application", "sentiment": {"score": -0.78439, "label": "negative"}, "relevance": 0.51698, "count": 1}, {"text": "factor", "sentiment": {"score": -0.323294, "label": "negative"}, "relevance": 0.51639, "count": 1}]}, "extracted_metadata": {"sha1": "3185c921c7e929d7b7c37985bba9bb2d4118c7ea", "filename": "1542982447074.zip-b5b4f75ef078d04ada0aaf3b15654734.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/925", "https://www.marketresearchfuture.com/reports/precision-medicine-market-925"], "title": "Precision Medicine Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2017-2022", "forum_title": "ABNewswire \u2013 Press Release Distribution Service \u2013 Paid Press Release Distribution Newswire"}, {"id": "vDgStvP2QS-up8L32m85mp-SDeJN7blifG6HbUV_PBTBFg-FMJsoWvac_u1a6mU9", "result_metadata": {"score": 29.528545}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Natural killer cell", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Natural_killer_cell"}], "categories": [{"score": 0.627964, "label": "/science/weather"}, {"score": 0.588624, "label": "/science/weather/meteorological disaster/hurricane"}, {"score": 0.570246, "label": "/automotive and vehicles/cars/hybrid"}], "relations": [], "keywords": [{"text": "Global NK Cells Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999735, "count": 1}, {"text": "Manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.802705, "count": 1}, {"text": "Regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.760851, "count": 1}, {"text": "Type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.722022, "count": 1}, {"text": "Application", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.687236, "count": 1}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.656845, "count": 1}]}, "crawl_date": "2018-11-23T07:42:22Z", "url": "https://www.wesrch.com/medical/paper-details/press-paper-ME1XXF000PHAM-global-nk-cells-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023", "host": "wesrch.com", "text": "Ltd.", "main_image_url": "https://www.wesrch.com/assets/images/logo.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T07:24:00Z", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": 0.453773, "label": "positive"}, "text": "NK Cells", "relevance": 0.906239, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.373873, "label": "positive"}, "text": "Global NK Cells", "relevance": 0.392095, "type": "Company"}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "USA", "relevance": 0.164493, "type": "Organization", "disambiguation": {"subtype": ["Location", "Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SACHIN JAIN", "relevance": 0.154122, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "industry development", "relevance": 0.152122, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.121905, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.117086, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.116435, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sorrento Therapeutics Inc.", "relevance": 0.115985, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Algoro Research Consultants Pvt", "relevance": 0.115809, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NKT Therapeutics", "relevance": 0.115627, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chipscreen Biosciences", "relevance": 0.115145, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.269972, "label": "positive"}, "text": "Innate Pharma SA", "relevance": 0.113783, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Altor BioScience Corporation", "relevance": 0.111391, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Affimed NV", "relevance": 0.108445, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Netherlands", "relevance": 0.106551, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.105938, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.353473, "label": "positive"}, "text": "China", "relevance": 0.105904, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NantKwest Inc.", "relevance": 0.103223, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.103223, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.785204, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "You"}, "sentence": "You have Already saved this Press Release to your Library.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "You"}, "sentence": "You have Already saved this Press Release to your Library.", "object": {"text": "this Press Release", "keywords": [{"text": "Press Release"}], "entities": []}, "action": {"verb": {"text": "save", "tense": "past"}, "text": "saved", "normalized": "save"}}, {"subject": {"text": "SACHIN JAIN 22nd-Nov-2018 23 Global NK Cells Market", "keywords": [{"text": "Global NK Cells"}, {"text": "SACHIN JAIN"}, {"text": "Market"}], "entities": [{"type": "Person", "text": "SACHIN JAIN"}]}, "sentence": " Global NK Cells Market 2018 By Manufacturers, Regions, Type And Application, Forecast To 2023 SACHIN JAIN 22nd-Nov-2018 23 Global NK Cells Market provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.", "object": {"text": "a basic overview of the industry including definitions, classifications, applications and industry chain structure", "keywords": [{"text": "industry chain structure"}, {"text": "basic overview"}, {"text": "classifications"}, {"text": "definitions"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The NK Cells Market analysis", "keywords": [{"text": "NK Cells Market"}], "entities": [{"type": "Company", "text": "NK Cells"}]}, "sentence": " The NK Cells Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.", "object": {"text": "provided for the international markets", "keywords": [{"text": "international markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The NK Cells Market analysis", "keywords": [{"text": "NK Cells Market"}], "entities": [{"type": "Company", "text": "NK Cells"}]}, "sentence": " The NK Cells Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.", "object": {"text": "for the international markets including development trends, competitive landscape analysis, and key regions development status", "keywords": [{"text": "key regions development"}, {"text": "competitive landscape analysis"}, {"text": "development trends"}, {"text": "international markets"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "development trends, competitive landscape analysis, and key regions development status", "keywords": [{"text": "key regions development"}, {"text": "competitive landscape analysis"}, {"text": "development trends"}]}, "sentence": " The NK Cells Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.", "object": {"text": "the international markets", "keywords": [{"text": "international markets"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "@ https://www.reportsandmarkets.com/sample-request/global-NK Cells -market-research-report-2018 The report", "keywords": [{"text": "https://www.reportsandmarkets.com/sample-request/global-NK Cells"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "sentence": " For Sample report @ https://www.reportsandmarkets.com/sample-request/global-NK Cells -market-research-report-2018 The report provides key statistics on the market status of the NK Cells manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.", "object": {"text": "key statistics", "keywords": [{"text": "key statistics"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Development policies and plans", "keywords": [{"text": "Development policies"}, {"text": "plans"}]}, "sentence": " Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.", "object": {"text": "discussed as well as manufacturing processes", "keywords": [{"text": "manufacturing processes"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.", "object": {"text": "import/export consumption, supply and demand Figures, cost, price, revenue and gross margins", "keywords": [{"text": "import/export consumption"}, {"text": "gross margins"}, {"text": "demand Figures"}, {"text": "revenue"}]}, "action": {"verb": {"text": "state", "tense": "present"}, "text": "states", "normalized": "state"}}, {"subject": {"text": "@ https://www.reportsandmarkets.com/check-discount/global-NK Cells -market-research-report-2018 Key Companies Analysis", "keywords": [{"text": "Key Companies Analysis"}, {"text": "https://www.reportsandmarkets.com/check-discount/global-NK Cells"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "sentence": " Complete report on NK Cells market spreads across 116 pagesprofiling 09 companies and supported with 191 tables and figures @ https://www.reportsandmarkets.com/check-discount/global-NK Cells -market-research-report-2018 Key Companies Analysis: Chipscreen Biosciences (China) ,Affimed NV (Netherlands) ,Altor BioScience Corporation (USA) ,Innate Pharma SA (France) ,Takeda Pharmaceutical (Japan) ,Sorrento Therapeutics Inc. (USA) ,NantKwest Inc. (USA) ,Bristol-Myers Squibb (USA) ,NKT Therapeutics (USA) .", "object": {"text": "with 191 tables and figures", "keywords": [{"text": "tables"}, {"text": "figures"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "supported", "normalized": "support"}}, {"subject": {"text": "industry players", "keywords": [{"text": "industry players"}]}, "sentence": " Global NK Cells Market focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information.", "object": {"text": "information such as company profiles", "keywords": [{"text": "company profiles"}, {"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "the feasibility of new investment projects", "keywords": [{"text": "new investment projects"}, {"text": "feasibility"}]}, "sentence": " Finally the feasibility of new investment projects are assessed and overall research conclusions offered.", "object": {"text": "overall research conclusions", "keywords": [{"text": "overall research conclusions"}]}, "action": {"verb": {"text": "assess", "tense": "past"}, "text": "are assessed", "normalized": "be assess"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.", "object": {"text": "key statistics", "keywords": [{"text": "key statistics"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Reports And Markets", "keywords": [{"text": "Reports"}, {"text": "Markets"}]}, "sentence": " Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "object": {"text": "an exhaustive list of market research reports", "keywords": [{"text": "exhaustive list"}, {"text": "market research reports"}]}, "action": {"verb": {"text": "feature", "tense": "present"}, "text": "features", "normalized": "feature"}}, {"subject": {"text": "We"}, "sentence": " We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.", "object": {"text": "a database spanning virtually every market category", "keywords": [{"text": "market category"}, {"text": "database"}]}, "action": {"verb": {"text": "boast", "tense": "present"}, "text": "boast", "normalized": "boast"}}, {"subject": {"text": "The Reports And Markets team", "keywords": [{"text": "Markets team"}, {"text": "Reports"}]}, "sentence": " The Reports And Markets team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.", "object": {"text": "itself"}, "action": {"verb": {"text": "pride", "tense": "present"}, "text": "prides", "normalized": "pride"}}], "concepts": [{"text": "Supply and demand", "relevance": 0.949455, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}, {"text": "Manufacturing", "relevance": 0.948565, "dbpedia_resource": "http://dbpedia.org/resource/Manufacturing"}, {"text": "Revenue", "relevance": 0.835669, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Market", "relevance": 0.704873, "dbpedia_resource": "http://dbpedia.org/resource/Market"}, {"text": "Gross margin", "relevance": 0.688501, "dbpedia_resource": "http://dbpedia.org/resource/Gross_margin"}, {"text": "Capitalism", "relevance": 0.654038, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}, {"text": "Trade", "relevance": 0.643246, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Cost", "relevance": 0.637953, "dbpedia_resource": "http://dbpedia.org/resource/Cost"}, {"text": "Marketing", "relevance": 0.588857, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Report", "relevance": 0.58543, "dbpedia_resource": "http://dbpedia.org/resource/Report"}, {"text": "Globalization", "relevance": 0.583888, "dbpedia_resource": "http://dbpedia.org/resource/Globalization"}, {"text": "Natural killer cell", "relevance": 0.57156, "dbpedia_resource": "http://dbpedia.org/resource/Natural_killer_cell"}, {"text": "Abbas Kiarostami", "relevance": 0.534233, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}, {"text": "Markets", "relevance": 0.5325, "dbpedia_resource": "http://dbpedia.org/resource/Markets"}], "categories": [{"score": 0.756947, "label": "/business and industrial/company/earnings"}, {"score": 0.727602, "label": "/finance/investing"}, {"score": 0.727602, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "partOf", "sentence": "Global NK Cells Market 2018 By Manufacturers, Regions, Type And Application, Forecast To 2023 SACHIN JAIN 22nd-Nov-2018 23 Global NK Cells Market provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.", "score": 0.741421, "arguments": [{"text": "Manufacturers", "location": [90, 103], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Global NK Cells Market", "location": [59, 81], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "For Sample report @ https://www.reportsandmarkets.com/sample-request/global-NK Cells -market-research-report-2018 The report provides key statistics on the market status of the NK Cells manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.", "score": 0.874713, "arguments": [{"text": "manufacturers", "location": [685, 698], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NK Cells", "location": [676, 684], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.614762, "arguments": [{"text": "Analysis", "location": [2637, 2645], "entities": [{"type": "Organization", "text": "Key Companies Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NK Cells", "location": [2649, 2657], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.708169, "arguments": [{"text": "Analysis", "location": [2748, 2756], "entities": [{"type": "Organization", "text": "Key Companies Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NK Cells", "location": [2760, 2768], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.874859, "arguments": [{"text": "6 Analyses", "location": [2669, 2679], "entities": [{"type": "Person", "text": "6 Analyses"}]}, {"text": "NK Cells Production", "location": [2683, 2702], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.830631, "arguments": [{"text": "6 Analyses", "location": [2669, 2679], "entities": [{"type": "Person", "text": "6 Analyses"}]}, {"text": "Supply", "location": [2704, 2710], "entities": [{"type": "Organization", "text": "Supply", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.444479, "arguments": [{"text": "NK Cells Production", "location": [2683, 2702], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Supply", "location": [2704, 2710], "entities": [{"type": "Organization", "text": "Supply", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.453007, "arguments": [{"text": "Key Manufacturers 8 Price", "location": [2778, 2803], "entities": [{"type": "Organization", "text": "Key Manufacturers 8 Price", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NK Cells", "location": [2760, 2768], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.84334, "arguments": [{"text": "10Development Trend", "location": [2886, 2905], "entities": [{"type": "Person", "text": "10Development Trend"}]}, {"text": "NK Cells", "location": [2877, 2885], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.4985, "arguments": [{"text": "10Development Trend", "location": [2886, 2905], "entities": [{"type": "Person", "text": "10Development Trend"}]}, {"text": "NK Cells", "location": [2909, 2917], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.625275, "arguments": [{"text": "10Development Trend", "location": [2886, 2905], "entities": [{"type": "Person", "text": "10Development Trend"}]}, {"text": "Industry Chain Suppliers", "location": [2939, 2963], "entities": [{"type": "Organization", "text": "Industry Chain Suppliers"}]}]}, {"type": "partOf", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.695768, "arguments": [{"text": "Industry Chain Suppliers", "location": [2939, 2963], "entities": [{"type": "Organization", "text": "Industry Chain Suppliers"}]}, {"text": "NK Cells", "location": [2967, 2975], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.377229, "arguments": [{"text": "NK Cells", "location": [2967, 2975], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Contact Information", "location": [2981, 3000], "entities": [{"type": "Organization", "text": "Contact Information", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.569079, "arguments": [{"text": "Conclusion", "location": [3063, 3073], "entities": [{"type": "Organization", "text": "Conclusion"}]}, {"text": "NK Cells", "location": [3051, 3059], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global NK Cells Market 2018 By Manufacturers, Regions, Type And Application, Forecast To 2023 SACHIN JAIN 22nd-Nov-2018 23 Global NK Cells Market provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.", "score": 0.45632, "arguments": [{"text": "SACHIN JAIN 22nd-Nov", "location": [153, 173], "entities": [{"type": "Person", "text": "SACHIN JAIN 22nd-Nov"}]}, {"text": "Global NK Cells Market", "location": [182, 204], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.327366, "arguments": [{"text": "Conclusion", "location": [3063, 3073], "entities": [{"type": "Organization", "text": "Conclusion"}]}, {"text": "Global NK Cells industry", "location": [3081, 3105], "entities": [{"type": "Organization", "text": "Global NK Cells industry", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.496494, "arguments": [{"text": "Direct Purchase This Report@", "location": [3161, 3189], "entities": [{"type": "Organization", "text": "Direct Purchase This Report@"}]}, {"text": "https://www.reportsandmarkets.com/checkout?currency=one_user-USD", "location": [3190, 3254], "entities": [{"type": "Web", "text": "https://www.reportsandmarkets.com/checkout?currency=one_user-USD"}]}]}, {"type": "employedBy", "sentence": "Marketing Traders or Distributor Analysis of NK Cells 10Development Trend of NK Cells industry2018-2023 11 Industry Chain Suppliers of NK Cells with Contact Information 12 New Project Investment Feasibility Analysis of NK Cells 13 Conclusion of the Global NK Cells industry 2018 Market Research Report List of Tables and Figures Direct Purchase This Report@ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622 About Us: Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. Reports And Markets features an exhaustive list of market research reports from hundreds of publishers worldwide.", "score": 0.797515, "arguments": [{"text": "&report_id=2579622", "location": [3254, 3272], "entities": [{"type": "Person", "text": "&report_id=2579622"}]}, {"text": "Us", "location": [3279, 3281], "entities": [{"type": "Organization", "text": "NantKwest Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Complete report on NK Cells market spreads across 116 pagesprofiling 09 companies and supported with 191 tables and figures @ https://www.reportsandmarkets.com/check-discount/global-NK Cells -market-research-report-2018 Key Companies Analysis: Chipscreen Biosciences (China) ,Affimed NV (Netherlands) ,Altor BioScience Corporation (USA) ,Innate Pharma SA (France) ,Takeda Pharmaceutical (Japan) ,Sorrento Therapeutics Inc. (USA) ,NantKwest Inc. (USA) ,Bristol-Myers Squibb (USA) ,NKT Therapeutics (USA) .", "score": 0.410921, "arguments": [{"text": "Innate Pharma SA", "location": [1383, 1399], "entities": [{"type": "Organization", "text": "Innate Pharma SA"}]}, {"text": "France", "location": [1401, 1407], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "Complete report on NK Cells market spreads across 116 pagesprofiling 09 companies and supported with 191 tables and figures @ https://www.reportsandmarkets.com/check-discount/global-NK Cells -market-research-report-2018 Key Companies Analysis: Chipscreen Biosciences (China) ,Affimed NV (Netherlands) ,Altor BioScience Corporation (USA) ,Innate Pharma SA (France) ,Takeda Pharmaceutical (Japan) ,Sorrento Therapeutics Inc. (USA) ,NantKwest Inc. (USA) ,Bristol-Myers Squibb (USA) ,NKT Therapeutics (USA) .", "score": 0.481747, "arguments": [{"text": "Takeda Pharmaceutical", "location": [1410, 1431], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "Japan", "location": [1433, 1438], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Complete report on NK Cells market spreads across 116 pagesprofiling 09 companies and supported with 191 tables and figures @ https://www.reportsandmarkets.com/check-discount/global-NK Cells -market-research-report-2018 Key Companies Analysis: Chipscreen Biosciences (China) ,Affimed NV (Netherlands) ,Altor BioScience Corporation (USA) ,Innate Pharma SA (France) ,Takeda Pharmaceutical (Japan) ,Sorrento Therapeutics Inc. (USA) ,NantKwest Inc. (USA) ,Bristol-Myers Squibb (USA) ,NKT Therapeutics (USA) .", "score": 0.396664, "arguments": [{"text": "NKT Therapeutics", "location": [1525, 1541], "entities": [{"type": "Organization", "text": "NKT Therapeutics"}]}, {"text": "USA", "location": [1543, 1546], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.59419, "arguments": [{"text": "Overview 2 Manufacturing Cost Structure Analysis", "location": [2430, 2478], "entities": [{"type": "Organization", "text": "Overview 2 Manufacturing Cost Structure Analysis"}]}, {"text": "Table of Contents", "location": [2400, 2417], "entities": [{"type": "GeopoliticalEntity", "text": "Table of Contents"}]}]}, {"type": "partOf", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.689645, "arguments": [{"text": "Overview 2 Manufacturing Cost Structure Analysis", "location": [2430, 2478], "entities": [{"type": "Organization", "text": "Overview 2 Manufacturing Cost Structure Analysis"}]}, {"text": "NK Cells 3 Technical Data", "location": [2482, 2507], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.46086, "arguments": [{"text": "Manufacturing Plants Analysis 4 Production Analysis", "location": [2512, 2563], "entities": [{"type": "Organization", "text": "Manufacturing Plants Analysis 4 Production Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NK Cells", "location": [2567, 2575], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Make an Enquiry before buying this Report @ https://www.reportsandmarkets.com/enquiry/global-NK Cells -market-research-report-2018 Major Points Covered in Table of Contents: 1 Industry Overview 2 Manufacturing Cost Structure Analysis of NK Cells 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of NK Cells by Regions, Technology, and Applications 5 Sales and Revenue Analysis of NK Cells by Regions 6 Analyses of NK Cells Production, Supply, Sales and Market Status 2010-2018 7 Analysis of NK Cells industry Key Manufacturers 8 Price and Gross Margin Analysis 9", "score": 0.297964, "arguments": [{"text": "NK Cells", "location": [2567, 2575], "entities": [{"type": "Organization", "text": "NK Cells 3 Technical Data", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Regions", "location": [2579, 2586], "entities": [{"type": "Location", "text": "Regions"}]}]}], "keywords": [{"text": "Global NK Cells Market", "sentiment": {"score": 0.953068, "label": "positive"}, "relevance": 0.920481, "count": 2}, {"text": "Sample report", "sentiment": {"score": 0.99162, "label": "positive"}, "relevance": 0.760507, "count": 1}, {"text": "NK Cells Market analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.760403, "count": 1}, {"text": "market-research-report", "sentiment": {"score": 0.769163, "mixed": "1", "label": "positive"}, "relevance": 0.671171, "count": 3}, {"text": "basic overview of the industry", "sentiment": {"score": 0.953068, "label": "positive"}, "relevance": 0.618765, "count": 1}, {"text": "report", "sentiment": {"score": 0.773854, "mixed": "1", "label": "positive"}, "relevance": 0.612209, "count": 3}, {"text": "international markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59883, "count": 1}, {"text": "market status of the NK Cells manufacturers", "sentiment": {"score": 0.99162, "label": "positive"}, "relevance": 0.584217, "count": 1}, {"text": "competitive landscape analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58189, "count": 1}, {"text": "key regions development status", "sentiment": {"score": 0.99162, "label": "positive"}, "relevance": 0.574606, "count": 1}, {"text": "development trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563157, "count": 1}, {"text": "NK Cells market spreads", "sentiment": {"score": -0.486324, "label": "negative"}, "relevance": 0.559807, "count": 1}, {"text": "Major Points", "sentiment": {"score": 0.955808, "label": "positive"}, "relevance": 0.556891, "count": 1}, {"text": "industry", "sentiment": {"score": 0.99162, "label": "positive"}, "relevance": 0.556443, "count": 1}, {"text": "feasibility of new investment projects", "sentiment": {"score": 0.788707, "label": "positive"}, "relevance": 0.556195, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.85485, "label": "positive"}, "relevance": 0.553121, "count": 1}, {"text": "manufacturing processes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55288, "count": 1}, {"text": "raw materials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552225, "count": 1}, {"text": "https://www.reportsandmarkets.com/sample-request/global-NK Cells", "sentiment": {"score": 0.99162, "label": "positive"}, "relevance": 0.549795, "count": 1}, {"text": "companies", "sentiment": {"score": 0.783483, "mixed": "1", "label": "positive"}, "relevance": 0.549496, "count": 3}, {"text": "Key Companies Analysis", "sentiment": {"score": -0.486324, "label": "negative"}, "relevance": 0.544676, "count": 1}, {"text": "Global NK Cells Market focuses", "sentiment": {"score": 0.85485, "label": "positive"}, "relevance": 0.544658, "count": 1}, {"text": "Report", "sentiment": {"score": 0.94407, "label": "positive"}, "relevance": 0.542703, "count": 2}, {"text": "Regions", "sentiment": {"score": 0.95488, "label": "positive"}, "relevance": 0.541658, "count": 3}, {"text": "Bristol-Myers Squibb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540321, "count": 1}, {"text": "industry chain structure", "sentiment": {"score": 0.953068, "label": "positive"}, "relevance": 0.540056, "count": 1}, {"text": "tables", "sentiment": {"score": 0.618499, "mixed": "1", "label": "positive"}, "relevance": 0.539415, "count": 2}, {"text": "market", "sentiment": {"score": 0.955808, "label": "positive"}, "relevance": 0.538343, "count": 1}, {"text": "Technical Data", "sentiment": {"score": 0.955808, "label": "positive"}, "relevance": 0.538193, "count": 1}, {"text": "figures", "sentiment": {"score": -0.486324, "label": "negative"}, "relevance": 0.535049, "count": 1}, {"text": "Application", "sentiment": {"score": 0.953068, "label": "positive"}, "relevance": 0.533045, "count": 1}, {"text": "applications", "sentiment": {"score": 0.953068, "label": "positive"}, "relevance": 0.533045, "count": 1}, {"text": "information", "sentiment": {"score": 0.85485, "label": "positive"}, "relevance": 0.532717, "count": 1}, {"text": "Manufacturers", "sentiment": {"score": 0.953068, "label": "positive"}, "relevance": 0.531079, "count": 1}, {"text": "Contact Information", "sentiment": {"score": 0.932034, "label": "positive"}, "relevance": 0.530287, "count": 1}, {"text": "production", "sentiment": {"score": 0.85485, "label": "positive"}, "relevance": 0.529469, "count": 1}, {"text": "NK Cells industry development trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528786, "count": 1}, {"text": "Reports", "sentiment": {"score": 0.820961, "label": "positive"}, "relevance": 0.528507, "count": 2}, {"text": "Markets", "sentiment": {"score": 0.606261, "label": "positive"}, "relevance": 0.527414, "count": 1}, {"text": "cost", "sentiment": {"score": 0.479234, "mixed": "1", "label": "positive"}, "relevance": 0.526693, "count": 2}, {"text": "Figures", "sentiment": {"score": 0.932034, "label": "positive"}, "relevance": 0.523387, "count": 1}, {"text": "price", "sentiment": {"score": 0.479234, "mixed": "1", "label": "positive"}, "relevance": 0.523369, "count": 2}, {"text": "Sales", "sentiment": {"score": 0.955808, "label": "positive"}, "relevance": 0.522492, "count": 2}, {"text": "Applications", "sentiment": {"score": 0.955808, "label": "positive"}, "relevance": 0.522048, "count": 1}, {"text": "revenue", "sentiment": {"score": 0.479234, "mixed": "1", "label": "positive"}, "relevance": 0.52161, "count": 2}, {"text": "demand Figures", "sentiment": {"score": -0.591124, "label": "negative"}, "relevance": 0.520163, "count": 1}, {"text": "Supply", "sentiment": {"score": 0.955808, "label": "positive"}, "relevance": 0.520018, "count": 1}, {"text": "supply", "sentiment": {"score": -0.591124, "label": "negative"}, "relevance": 0.520018, "count": 1}, {"text": "valuable source of guidance", "sentiment": {"score": 0.983958, "label": "positive"}, "relevance": 0.51954, "count": 2}, {"text": "Complete report", "sentiment": {"score": -0.486324, "label": "negative"}, "relevance": 0.519348, "count": 1}]}, "extracted_metadata": {"sha1": "075d55f858d7cd4e5c48937ae2fcd1f190cdf2e3", "filename": "1542958942341.zip-48d7e4cbccd636c979f5eca69d73eeb0.xml", "file_type": "json"}, "external_links": ["https://www.reportsandmarkets.com/check-discount/global-NK", "https://www.reportsandmarkets.com/check-discount/global-nk-cells-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023", "https://www.reportsandmarkets.com/enquiry/global-nk-cells-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023", "https://www.reportsandmarkets.com/sample-request/global-NK", "https://www.reportsandmarkets.com/enquiry/global-NK", "https://www.reportsandmarkets.com/reports/global-nk-cells-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023", "https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2579622", "https://www.reportsandmarkets.com/sample-request/global-nk-cells-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023"], "title": "Global NK Cells Market 2018 By Manufacturers, Regions, Type And Application, Forecast To 2023", "forum_title": "WeSRCH.com: Latest Press Release"}, {"id": "VK1-4t3KkEwiH1yy8I4FdGaFFYI3H-J_mrsrN-7n6cyeC2RIQR8mbunz_sgl1OWn", "result_metadata": {"score": 27.317715}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.296334, "label": "negative"}, "text": "Therapeutics Review", "relevance": 0.33, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": -0.296334, "label": "negative"}, "text": "GlaxoSmithKline Plc.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.210403, "label": "negative"}, "text": "Bayer AG", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0.22794, "label": "positive"}, "text": "Amgen, Inc.", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.589609, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Saxagliptin", "relevance": 0.971265, "dbpedia_resource": "http://dbpedia.org/resource/Saxagliptin"}, {"text": "Bristol-Myers Squibb", "relevance": 0.96844, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Pharmaceutical industry", "relevance": 0.928729, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Dapagliflozin", "relevance": 0.921318, "dbpedia_resource": "http://dbpedia.org/resource/Dapagliflozin"}, {"text": "Multinational companies", "relevance": 0.803185, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.717119, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}], "categories": [{"score": 0.883766, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Cowden Syndrome Market", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.938599, "count": 1}, {"text": "Clinical Trials", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.882979, "count": 1}, {"text": "Key Competitors Upto", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.667257, "count": 1}, {"text": "GlaxoSmithKline Plc", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.632886, "count": 1}, {"text": "Amgen", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.621222, "count": 1}, {"text": "Company", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.618797, "count": 1}, {"text": "Therapeutics Review", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.611747, "count": 1}, {"text": "others", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.536663, "count": 1}, {"text": "Bayer AG", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.529072, "count": 1}, {"text": "Eli Lilly", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.45689, "count": 1}, {"text": "AstraZeneca Plc", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.425949, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.409676, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0.589609, "label": "positive"}, "relevance": 0.271839, "count": 1}]}, "crawl_date": "2018-11-23T10:23:14Z", "url": "https://www.openpr.com/news/1394890/Cowden-Syndrome-Market-2018-Clinical-Trials-and-Therapeutics-Review-and-Key-Competitors-Upto-2023-GlaxoSmithKline-Plc-Bayer-AG-Amgen-Inc-Eli-Lilly-and-Company-AstraZeneca-Plc-Bristol-Myers-Squibb-Company-and-others.html", "host": "openpr.com", "text": "(U.K.), Bayer AG (Germany), Takeda Pharmaceuticals (Japan), Pfizer, Inc.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T10:22:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.72777, "label": "negative"}, "text": "Cowden", "relevance": 0.668784, "type": "Person"}, {"count": 4, "sentiment": {"score": -0.265266, "label": "negative"}, "text": "Cowden", "relevance": 0.575128, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": -0.504433, "label": "negative"}, "text": "Cowden Syndrome", "relevance": 0.5381, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": -0.72053, "label": "negative"}, "text": "tumor syndrome", "relevance": 0.335386, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": -0.478851, "label": "negative"}, "text": "Middle East", "relevance": 0.252917, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 9, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.249147, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.368363, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.202315, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": -0.470086, "label": "negative"}, "text": "Asia Pacific", "relevance": 0.191834, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.190918, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.187831, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.72053, "label": "negative"}, "text": "PTEN", "relevance": 0.187001, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.245493, "label": "negative"}, "text": "Bayer AG", "relevance": 0.186597, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.186482, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.182325, "type": "Person", "disambiguation": {"subtype": [], "name": "Eli Lilly (industrialist)", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_(industrialist)"}}, {"count": 1, "sentiment": {"score": -0.43099, "label": "negative"}, "text": "Oncomed Pharmaceuticals", "relevance": 0.179811, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Janssen Biotech", "relevance": 0.179518, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"count": 1, "sentiment": {"score": -0.376628, "label": "negative"}, "text": "Spectrum Pharmaceuticals Inc.", "relevance": 0.179138, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.174482, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.173884, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": -0.238539, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.171525, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.438496, "label": "negative"}, "text": "Africa", "relevance": 0.169302, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.167518, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.167263, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.166469, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.164098, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.312313, "label": "positive"}, "text": "Amgen, Inc.", "relevance": 0.162025, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc.", "relevance": 0.160555, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kuwait", "relevance": 0.159497, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "Country"], "name": "Kuwait", "dbpedia_resource": "http://dbpedia.org/resource/Kuwait"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc.", "relevance": 0.159166, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.156804, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.156798, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.728267, "label": "negative"}, "text": "Africa", "relevance": 0.153166, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.152957, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.152645, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Qatar", "relevance": 0.137655, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Qatar", "dbpedia_resource": "http://dbpedia.org/resource/Qatar"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oman", "relevance": 0.13666, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Oman", "dbpedia_resource": "http://dbpedia.org/resource/Oman"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "South Arabia", "relevance": 0.12957, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.12957, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.7%", "relevance": 0.12957, "type": "Quantity"}], "sentiment": {"document": {"score": -0.430112, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Cowden Syndrome Market over the forecast period.Market Scenario:Cowden syndrome is part of the PTEN hamartoma tumor syndrome", "keywords": [{"text": "PTEN hamartoma tumor"}, {"text": "Global Cowden Syndrome"}, {"text": "forecast period.Market Scenario"}, {"text": "current market scenario"}], "entities": [{"type": "Person", "text": "Cowden"}, {"type": "Organization", "text": "PTEN"}, {"type": "HealthCondition", "text": "tumor syndrome"}]}, "sentence": "Press release from: Market Research Future Cowden Syndrome Market This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Cowden Syndrome Market over the forecast period.Market Scenario:Cowden syndrome is part of the PTEN hamartoma tumor syndrome.", "object": {"text": "Market Research Future Cowden Syndrome Market This study", "keywords": [{"text": "Research Future Cowden"}, {"text": "Syndrome Market"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "Cowden syndrome", "keywords": [{"text": "Cowden syndrome"}], "entities": [{"type": "Person", "text": "Cowden"}]}, "sentence": "Press release from: Market Research Future Cowden Syndrome Market This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Cowden Syndrome Market over the forecast period.Market Scenario:Cowden syndrome is part of the PTEN hamartoma tumor syndrome.", "object": {"text": "part of the PTEN hamartoma tumor syndrome", "keywords": [{"text": "PTEN hamartoma tumor"}], "entities": [{"type": "Organization", "text": "PTEN"}, {"type": "HealthCondition", "text": "tumor syndrome"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin", "keywords": [{"text": "cancerous tumors"}, {"text": "high risk"}, {"text": "colorectal"}, {"text": "kidney"}]}, "sentence": " Cowden syndrome is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin.", "object": {"text": "Cowden syndrome", "keywords": [{"text": "Cowden syndrome"}], "entities": [{"type": "Person", "text": "Cowden"}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "The global Cowden syndrome market", "keywords": [{"text": "global Cowden syndrome"}], "entities": []}, "sentence": " The global Cowden syndrome market is expecting a healthy growth in the coming future.", "object": {"text": "expecting a healthy growth", "keywords": [{"text": "healthy growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global Cowden syndrome market", "keywords": [{"text": "global Cowden syndrome"}], "entities": []}, "sentence": " The global Cowden syndrome market is expecting a healthy growth in the coming future.", "object": {"text": "a healthy growth", "keywords": [{"text": "healthy growth"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "is expecting", "normalized": "be expect"}}, {"subject": {"text": "The global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " The global market is majorly driven by increasing Cowden syndrome patients across the globe.", "object": {"text": "majorly driven by increasing Cowden syndrome patients across the globe", "keywords": [{"text": "Cowden syndrome patients"}, {"text": "globe"}], "entities": [{"type": "Person", "text": "Cowden"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by increasing Cowden syndrome patients across the globe", "keywords": [{"text": "Cowden syndrome patients"}, {"text": "globe"}], "entities": [{"type": "Person", "text": "Cowden"}]}, "sentence": " The global market is majorly driven by increasing Cowden syndrome patients across the globe.", "object": {"text": "The global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "driven", "normalized": "drive"}}, {"subject": {"text": "The global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " The global market is majorly driven by increasing Cowden syndrome patients across the globe.", "object": {"text": "Cowden syndrome", "keywords": [{"text": "Cowden syndrome"}], "entities": [{"type": "Person", "text": "Cowden"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": []}, "sentence": " Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market.", "object": {"text": "increasing smoking population and rising consumption of alcohol", "keywords": [{"text": "smoking population"}, {"text": "consumption"}, {"text": "alcohol"}]}, "action": {"verb": {"text": "spur", "tense": "past"}, "text": "have spurred", "normalized": "have spur"}}, {"subject": {"text": "The chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "sentence": " The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents.", "object": {"text": "further segmented into anthracyclines", "keywords": [{"text": "anthracyclines"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "sentence": " The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents.", "object": {"text": "into anthracyclines, taxanes, antimetabolites, and alkylating agents", "keywords": [{"text": "anthracyclines"}, {"text": "taxanes"}, {"text": "antimetabolites"}, {"text": "agents"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "The chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "sentence": " The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents.", "object": {"text": "agents", "keywords": [{"text": "agents"}]}, "action": {"verb": {"text": "alkylating", "tense": "present"}, "text": "alkylating", "normalized": "alkylating"}}, {"subject": {"text": "The targeted therapy", "keywords": [{"text": "targeted therapy"}]}, "sentence": " The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors.", "object": {"text": "sub-segmented"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hormone therapy", "keywords": [{"text": "Hormone therapy"}]}, "sentence": " Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.Regional AnalysisThe Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer.", "object": {"text": "further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.On the basis of end users", "keywords": [{"text": "selective estrogen-receptor modulators"}, {"text": "aromatase inhibitors"}, {"text": "end users"}, {"text": "basis"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hormone therapy", "keywords": [{"text": "Hormone therapy"}]}, "sentence": " Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.Regional AnalysisThe Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer.", "object": {"text": "into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.On the basis of end users", "keywords": [{"text": "selective estrogen-receptor modulators"}, {"text": "aromatase inhibitors"}, {"text": "end users"}, {"text": "basis"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "sentence": " Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.Regional AnalysisThe Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer.", "object": {"text": "segmented into hospital & clinics, ambulatory care centers", "keywords": [{"text": "ambulatory care centers"}, {"text": "hospital"}, {"text": "clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "others.Regional AnalysisThe Americas", "keywords": [{"text": "others.Regional AnalysisThe Americas"}]}, "sentence": " Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.Regional AnalysisThe Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer.", "object": {"text": "the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer", "keywords": [{"text": "global Cowden syndrome"}, {"text": "prevalence"}], "entities": [{"type": "Location", "text": "Cowden", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Person", "text": "Cowden"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominate", "normalized": "dominate"}}, {"subject": {"text": "high healthcare expenditure, well-developed technology, and strong government support for research & development", "keywords": [{"text": "high healthcare expenditure"}, {"text": "strong government support"}, {"text": "well-developed technology"}]}, "sentence": " Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market.", "object": {"text": "fuelled the growth of the Americas Cowden syndrome market", "keywords": [{"text": "Americas Cowden syndrome"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "high healthcare expenditure, well-developed technology, and strong government support for research & development", "keywords": [{"text": "high healthcare expenditure"}, {"text": "strong government support"}, {"text": "well-developed technology"}]}, "sentence": " Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market.", "object": {"text": "the growth of the Americas Cowden syndrome market", "keywords": [{"text": "Americas Cowden syndrome"}]}, "action": {"verb": {"text": "fuel", "tense": "past"}, "text": "have fuelled", "normalized": "have fuel"}}, {"subject": {"text": "Presence of the leading players and increasing availability of funds in this region", "keywords": [{"text": "Presence"}, {"text": "availability"}, {"text": "players"}, {"text": "funds"}]}, "sentence": " Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa.", "object": {"text": "the growth in the coming future.On the other hand", "keywords": [{"text": "growth"}, {"text": "future.On"}, {"text": "hand"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "the Middle East & Africa", "keywords": [{"text": "Middle East"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa.", "object": {"text": "the least share of the market", "keywords": [{"text": "share"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "hold", "normalized": "hold"}}, {"subject": {"text": "The Middle East", "keywords": [{"text": "Middle East"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " The Middle East holds the major share in the Middle East & Africa Cowden syndrome market.", "object": {"text": "the major share", "keywords": [{"text": "major share"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "Kuwait, Qatar, Oman, and South Arabia", "keywords": [{"text": "South Arabia"}, {"text": "Qatar"}, {"text": "Kuwait"}, {"text": "Oman"}], "entities": [{"type": "Location", "text": "Kuwait", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "Country"], "name": "Kuwait", "dbpedia_resource": "http://dbpedia.org/resource/Kuwait"}}, {"type": "Location", "text": "Qatar", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Qatar", "dbpedia_resource": "http://dbpedia.org/resource/Qatar"}}, {"type": "Location", "text": "Oman", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "Oman", "dbpedia_resource": "http://dbpedia.org/resource/Oman"}}, {"type": "Location", "text": "South Arabia", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market.", "object": {"text": "the major share of the Middle East market", "keywords": [{"text": "Middle East market"}, {"text": "major share"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "the African region", "keywords": [{"text": "African region"}]}, "sentence": " However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific.", "object": {"text": "expecting a healthy growth due to the presence of a huge opportunity for the development of the market.And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific", "keywords": [{"text": "largest Cowden syndrome"}, {"text": "huge opportunity"}, {"text": "healthy growth"}, {"text": "Europe accounts"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Cowden", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Organization", "text": "Asia Pacific"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the African region", "keywords": [{"text": "African region"}]}, "sentence": " However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific.", "object": {"text": "a healthy growth due to the presence of a huge opportunity for the development of the market.And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific", "keywords": [{"text": "largest Cowden syndrome"}, {"text": "huge opportunity"}, {"text": "healthy growth"}, {"text": "Europe accounts"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Cowden", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Organization", "text": "Asia Pacific"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "is expecting", "normalized": "be expect"}}, {"subject": {"text": "by the Asia Pacific", "keywords": [{"text": "Asia Pacific"}], "entities": [{"type": "Organization", "text": "Asia Pacific"}]}, "sentence": " However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific.", "object": {"text": "the second largest Cowden syndrome market", "keywords": [{"text": "largest Cowden syndrome"}], "entities": [{"type": "Location", "text": "Cowden", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "is followed", "normalized": "be follow"}}, {"subject": {"text": "Availability of the funds for research & development and strong government support", "keywords": [{"text": "strong government support"}, {"text": "Availability"}, {"text": "funds"}, {"text": "research"}]}, "sentence": " Availability of the funds for research & development and strong government support have driven the market growth.", "object": {"text": "driven the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Availability of the funds for research & development and strong government support", "keywords": [{"text": "strong government support"}, {"text": "Availability"}, {"text": "funds"}, {"text": "research"}]}, "sentence": " Availability of the funds for research & development and strong government support have driven the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "have driven", "normalized": "have drive"}}, {"subject": {"text": "The Asia Pacific", "keywords": [{"text": "Asia Pacific"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support.", "object": {"text": "the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support", "keywords": [{"text": "fastest growing Cowden"}, {"text": "syndrome market"}, {"text": "government support"}, {"text": "prevalence"}], "entities": [{"type": "Organization", "text": "Asia Pacific"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "India and China", "keywords": [{"text": "India"}, {"text": "China"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " India and China are expected to lead the market in this region.Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ www.marketresearchfuture.com/reports/cowden-syndrome-mark...", "object": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "are expected to lead", "normalized": "be expect to lead"}}], "concepts": [{"text": "Cancer", "relevance": 0.954017, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hamartoma", "relevance": 0.687151, "dbpedia_resource": "http://dbpedia.org/resource/Hamartoma"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.614334, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Bristol-Myers Squibb", "relevance": 0.605033, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Chemotherapy", "relevance": 0.544035, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Middle East", "relevance": 0.524555, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "Pharmaceutical industry", "relevance": 0.48635, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Islam", "relevance": 0.462764, "dbpedia_resource": "http://dbpedia.org/resource/Islam"}, {"text": "Asia", "relevance": 0.461768, "dbpedia_resource": "http://dbpedia.org/resource/Asia"}, {"text": "Oncology", "relevance": 0.442364, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Arabian Peninsula", "relevance": 0.424474, "dbpedia_resource": "http://dbpedia.org/resource/Arabian_Peninsula"}, {"text": "Cowden syndrome", "relevance": 0.417429, "dbpedia_resource": "http://dbpedia.org/resource/Cowden_syndrome"}, {"text": "Saudi Arabia", "relevance": 0.413481, "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}, {"text": "Clopidogrel", "relevance": 0.406895, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Medicine", "relevance": 0.383738, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Genentech", "relevance": 0.377104, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "United Arab Emirates", "relevance": 0.374183, "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}, {"text": "North Africa", "relevance": 0.373801, "dbpedia_resource": "http://dbpedia.org/resource/North_Africa"}, {"text": "PTEN", "relevance": 0.372643, "dbpedia_resource": "http://dbpedia.org/resource/PTEN_(gene)"}, {"text": "Paclitaxel", "relevance": 0.353994, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Signal transduction", "relevance": 0.352231, "dbpedia_resource": "http://dbpedia.org/resource/Signal_transduction"}, {"text": "Christianity", "relevance": 0.345857, "dbpedia_resource": "http://dbpedia.org/resource/Christianity"}, {"text": "Americas", "relevance": 0.33722, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Near East", "relevance": 0.335689, "dbpedia_resource": "http://dbpedia.org/resource/Near_East"}, {"text": "World War II", "relevance": 0.332891, "dbpedia_resource": "http://dbpedia.org/resource/World_War_II"}, {"text": "New York City", "relevance": 0.332859, "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}, {"text": "Qatar", "relevance": 0.33194, "dbpedia_resource": "http://dbpedia.org/resource/Qatar"}, {"text": "Arabic language", "relevance": 0.328113, "dbpedia_resource": "http://dbpedia.org/resource/Arabic_language"}], "categories": [{"score": 0.97122, "label": "/health and fitness/disease/cancer"}, {"score": 0.93881, "label": "/health and fitness/therapy"}, {"score": 0.929329, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "agentOf", "sentence": "Cowden syndrome is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin.", "score": 0.914381, "arguments": [{"text": "Cowden syndrome", "location": [351, 366], "entities": [{"type": "Organization", "text": "Americas Cowden syndrome"}]}, {"text": "characterized", "location": [370, 383], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "locatedAt", "sentence": "And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific.", "score": 0.749156, "arguments": [{"text": "Asia", "location": [3568, 3572], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3573, 3580], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support.", "score": 0.734454, "arguments": [{"text": "Asia", "location": [3700, 3704], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3705, 3712], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "employedBy", "sentence": "Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ www.marketresearchfuture.com/reports/cowden-syndrome-mark... Detailed Table of Contents for Cowden Syndrome Market1.", "score": 0.78496, "arguments": [{"text": "Market1", "location": [4136, 4143], "entities": [{"type": "Person", "text": "Market1"}]}, {"text": "Cowden Syndrome", "location": [4120, 4135], "entities": [{"type": "Organization", "text": "Americas Cowden syndrome"}]}]}, {"type": "employedBy", "sentence": "The global market is majorly driven by increasing Cowden syndrome patients across the globe.", "score": 0.435204, "arguments": [{"text": "patients", "location": [654, 662], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "Cowden syndrome", "location": [638, 653], "entities": [{"type": "Organization", "text": "Americas Cowden syndrome"}]}]}, {"type": "hasAttribute", "sentence": "The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.Get Sample Copy @ www.marketresearchfuture.com/sample_request/5096 Key PlayersSome of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc.", "score": 0.401642, "arguments": [{"text": "Sample Copy", "location": [1013, 1024], "entities": [{"type": "Person", "text": "Sample Copy"}]}, {"text": "@", "location": [1025, 1026], "entities": [{"type": "Money", "text": "@", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOfMany", "sentence": "The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.Get Sample Copy @ www.marketresearchfuture.com/sample_request/5096 Key PlayersSome of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc.", "score": 0.506878, "arguments": [{"text": "Sample Copy", "location": [1013, 1024], "entities": [{"type": "Person", "text": "Sample Copy"}]}, {"text": "players", "location": [1103, 1110], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOfMany", "sentence": "The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.Get Sample Copy @ www.marketresearchfuture.com/sample_request/5096 Key PlayersSome of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc.", "score": 0.687402, "arguments": [{"text": "www.marketresearchfuture.com/sample_request/", "location": [1027, 1071], "entities": [{"type": "Person", "text": "www.marketresearchfuture.com/sample_request/"}]}, {"text": "players", "location": [1103, 1110], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOfMany", "sentence": "The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.Get Sample Copy @ www.marketresearchfuture.com/sample_request/5096 Key PlayersSome of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc.", "score": 0.667352, "arguments": [{"text": "Key PlayersSome", "location": [1076, 1091], "entities": [{"type": "Person", "text": "Key PlayersSome"}]}, {"text": "players", "location": [1103, 1110], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOf", "sentence": "(U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), GlaxoSmithKline Plc.", "score": 0.347354, "arguments": [{"text": "U.S.)", "location": [1309, 1314], "entities": [{"type": "Organization", "text": "Spectrum Pharmaceuticals Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Novartis AG", "location": [1316, 1327], "entities": [{"type": "Organization", "text": "Novartis AG", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Regional AnalysisThe Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer.", "score": 0.994996, "arguments": [{"text": "AnalysisThe Americas", "location": [2483, 2503], "entities": [{"type": "Person", "text": "AnalysisThe Americas"}]}, {"text": "dominate", "location": [2504, 2512], "entities": [{"type": "EventCommunication", "text": "dominate"}]}]}, {"type": "hasAttribute", "sentence": "Regional AnalysisThe Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer.", "score": 0.719412, "arguments": [{"text": "people", "location": [2585, 2591], "entities": [{"type": "Person", "text": "people"}]}, {"text": "cancer", "location": [2627, 2633], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}], "keywords": [{"text": "radiation therapy", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.620028, "count": 1}, {"text": "market dynamics", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.597142, "count": 1}, {"text": "Middle East", "sentiment": {"score": -0.55976, "label": "negative"}, "relevance": 0.576438, "count": 3}, {"text": "current market scenario", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.570648, "count": 1}, {"text": "long time", "sentiment": {"score": -0.831772, "label": "negative"}, "relevance": 0.5673, "count": 1}, {"text": "Cowden syndrome", "sentiment": {"score": -0.567055, "mixed": "1", "label": "negative"}, "relevance": 0.564511, "count": 3}, {"text": "high risk", "sentiment": {"score": -0.918852, "label": "negative"}, "relevance": 0.563772, "count": 1}, {"text": "hormone therapy", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.561242, "count": 1}, {"text": "basis of site", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.559379, "count": 1}, {"text": "major countries", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.558578, "count": 1}, {"text": "global market", "sentiment": {"score": -0.845666, "label": "negative"}, "relevance": 0.558295, "count": 1}, {"text": "genetic testing", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.558128, "count": 1}, {"text": "therapy", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.557881, "count": 2}, {"text": "global Cowden syndrome market", "sentiment": {"score": -0.547661, "mixed": "1", "label": "negative"}, "relevance": 0.556909, "count": 4}, {"text": "Market Research Future Cowden Syndrome Market", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.554352, "count": 1}, {"text": "healthy growth", "sentiment": {"score": 0.43116, "label": "positive"}, "relevance": 0.553468, "count": 2}, {"text": "availability of funds", "sentiment": {"score": -0.565497, "label": "negative"}, "relevance": 0.548684, "count": 1}, {"text": "U.S.", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.546655, "count": 10}, {"text": "side effects of the treatment", "sentiment": {"score": -0.831772, "label": "negative"}, "relevance": 0.541599, "count": 1}, {"text": "Spectrum Pharmaceuticals Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541351, "count": 1}, {"text": "Press release", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.540011, "count": 1}, {"text": "others", "sentiment": {"score": -0.55425, "label": "negative"}, "relevance": 0.538834, "count": 3}, {"text": "major share", "sentiment": {"score": -0.556987, "label": "negative"}, "relevance": 0.536004, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.534946, "count": 1}, {"text": "research", "sentiment": {"score": 0.92681, "label": "positive"}, "relevance": 0.533766, "count": 2}, {"text": "Asia Pacific", "sentiment": {"score": 0.934091, "label": "positive"}, "relevance": 0.533723, "count": 2}, {"text": "South Arabia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532662, "count": 1}, {"text": "market", "sentiment": {"score": -0.468392, "mixed": "1", "label": "negative"}, "relevance": 0.532642, "count": 5}, {"text": "Market Scenario", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.532517, "count": 1}, {"text": "region", "sentiment": {"score": 0.4933, "mixed": "1", "label": "positive"}, "relevance": 0.532344, "count": 2}, {"text": "Hormone therapy", "sentiment": {"score": -0.520611, "label": "negative"}, "relevance": 0.530737, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529209, "count": 1}, {"text": "Kuwait", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529189, "count": 1}, {"text": "chemotherapy", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.527819, "count": 2}, {"text": "tyrosine kinase inhibitors", "sentiment": {"score": -0.520611, "label": "negative"}, "relevance": 0.527698, "count": 1}, {"text": "strong government support", "sentiment": {"score": 0.92681, "label": "positive"}, "relevance": 0.527693, "count": 2}, {"text": "India", "sentiment": {"score": 0.895125, "label": "positive"}, "relevance": 0.52689, "count": 1}, {"text": "part of the PTEN hamartoma tumor syndrome", "sentiment": {"score": -0.938121, "label": "negative"}, "relevance": 0.526435, "count": 1}, {"text": "end users", "sentiment": {"score": -0.612473, "label": "negative"}, "relevance": 0.526216, "count": 1}, {"text": "Presence", "sentiment": {"score": -0.565497, "label": "negative"}, "relevance": 0.526162, "count": 1}, {"text": "AbbVie Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525475, "count": 1}, {"text": "Switzerland", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525274, "count": 2}, {"text": "aromatase inhibitors", "sentiment": {"score": -0.520611, "label": "negative"}, "relevance": 0.524568, "count": 1}, {"text": "development", "sentiment": {"score": 0.92681, "label": "positive"}, "relevance": 0.524239, "count": 2}, {"text": "growth of the market", "sentiment": {"score": -0.831772, "label": "negative"}, "relevance": 0.524121, "count": 2}, {"text": "forecast period", "sentiment": {"score": -0.888926, "label": "negative"}, "relevance": 0.523914, "count": 2}, {"text": "sample", "sentiment": {"score": -0.831772, "label": "negative"}, "relevance": 0.52333, "count": 1}, {"text": "least share of the market", "sentiment": {"score": -0.565497, "label": "negative"}, "relevance": 0.522343, "count": 1}, {"text": "players", "sentiment": {"score": -0.712244, "label": "negative"}, "relevance": 0.522322, "count": 2}, {"text": "reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521804, "count": 1}]}, "extracted_metadata": {"sha1": "cdc6cf9d138153a9db94451243eeeae5a1aacad7", "filename": "1542968594935.zip-4aaf2710d59b19656583362ced66903f.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/5096", "https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096"], "title": "Cowden Syndrome Market 2018 Clinical Trials and Therapeutics Review and Key Competitors Upto 2023| GlaxoSmithKline Plc., Bayer AG, Amgen, Inc., Eli Lilly and Company , AstraZeneca Plc., Bristol-Myers Squibb Company and others", "forum_title": "openPR.com - Newsfeed"}, {"id": "Okey3YeaXugrHIdCphQEs3hMXs17wuRM9oyq8yJUTAft_nNYIRwoMcQQCuxqYD62", "result_metadata": {"score": 26.61102}, "author": "Prescient & Strategic Intelligence", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck Group", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Natus Medical Incorporated", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.246263, "label": "negative"}, "text": "Compumedics Limited", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Official", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "by Key Players Merck Group, Pfizer, Natus Medical Incorporated, Compumedics Limited - Official", "keywords": [{"text": "Key Players Merck"}, {"text": "Natus Medical Incorporated"}, {"text": "Pfizer"}, {"text": "Compumedics Limited"}], "entities": [{"type": "Company", "text": "Merck Group"}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Natus Medical Incorporated"}, {"type": "Company", "text": "Compumedics Limited"}, {"type": "JobTitle", "text": "Official"}]}, "sentence": "Sleeping Aids Market 2023 by Key Players Merck Group, Pfizer, Natus Medical Incorporated, Compumedics Limited - Official", "object": {"text": "Aids Market 2023", "keywords": [{"text": "Aids Market"}]}, "action": {"verb": {"text": "Sleeping", "tense": "present"}, "text": "Sleeping", "normalized": "Sleeping"}}], "concepts": [{"text": "Dow Jones Industrial Average", "relevance": 0.85551, "dbpedia_resource": "http://dbpedia.org/resource/Dow_Jones_Industrial_Average"}], "categories": [{"score": 0.999898, "label": "/health and fitness/disease/aids and hiv"}], "relations": [{"type": "employedBy", "sentence": "Sleeping Aids Market 2023 by Key Players Merck Group, Pfizer, Natus Medical Incorporated, Compumedics Limited - Official", "score": 0.573848, "arguments": [{"text": "Official", "location": [112, 120], "entities": [{"type": "Person", "text": "Official"}]}, {"text": "Compumedics Limited", "location": [90, 109], "entities": [{"type": "Organization", "text": "Compumedics Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Key Players Merck Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.906984, "count": 1}, {"text": "Aids Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.905421, "count": 1}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.714178, "count": 1}, {"text": "Natus Medical Incorporated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581941, "count": 1}, {"text": "Compumedics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.153797, "count": 1}, {"text": "Official", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.133906, "count": 1}]}, "crawl_date": "2018-11-22T17:06:25Z", "url": "https://www.openpr.com/news/1393097/Sleeping-Aids-Market-2023-by-Key-Players-Merck-Group-Pfizer-Natus-Medical-Incorporated-Compumedics-Limited-Official.html", "host": "openpr.com", "text": "., Takeda Pharmaceutical Co.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-22T16:51:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0.456879, "label": "positive"}, "text": "P&S Market Research", "relevance": 0.530966, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.382467, "label": "negative"}, "text": "sleeping pills", "relevance": 0.495028, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Royal Philips", "relevance": 0.465602, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.622791, "label": "negative"}, "text": "insomnia", "relevance": 0.454627, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0.687635, "label": "positive"}, "text": "Singapore Health Services", "relevance": 0.406493, "type": "Company", "disambiguation": {"subtype": [], "name": "SingHealth", "dbpedia_resource": "http://dbpedia.org/resource/SingHealth"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Koninklijke Philips N.V.", "relevance": 0.382559, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.377475, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philips APAC Center", "relevance": 0.370739, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.598362, "label": "negative"}, "text": "daytime drowsiness", "relevance": 0.368703, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.421531, "label": "positive"}, "text": "World Health Organization", "relevance": 0.367827, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Indian Medical Association", "relevance": 0.358473, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "Indian Medical Association", "dbpedia_resource": "http://dbpedia.org/resource/Indian_Medical_Association"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York City", "relevance": 0.345218, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.326399, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Respiratory Education Center", "relevance": 0.322031, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Michigan", "relevance": 0.318363, "type": "Organization", "disambiguation": {"subtype": ["Location", "AcademicInstitution", "CollegeUniversity", "University"], "name": "University of Michigan", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Michigan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore", "relevance": 0.315407, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Singapore", "dbpedia_resource": "http://dbpedia.org/resource/Singapore"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NPHA", "relevance": 0.314914, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.300687, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Natus Medical Inc.", "relevance": 0.298515, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cadwell Laboratories Inc.", "relevance": 0.288041, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.283883, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SleepMed Inc.", "relevance": 0.268875, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$100,0 billion", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$100 billion", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$280 billion", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$60 billion", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "80 years", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.0%", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "80%", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4%", "relevance": 0.268875, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8%", "relevance": 0.268875, "type": "Quantity"}], "sentiment": {"document": {"score": -0.323374, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "medicinal drugs and medical devices", "keywords": [{"text": "medicinal drugs"}, {"text": "medical devices"}]}, "sentence": "Press release from: Prescient & Strategic Intelligence Sleeping aids refer to medicinal drugs and medical devices that help a person to fall asleep.", "object": {"text": "a person to fall asleep", "keywords": [{"text": "person"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "medication", "keywords": [{"text": "medication"}]}, "sentence": " The various offering in sleeping aids market include medication, sleep laboratory services, mattresses and pillows, sleep apnea devices, and others.", "object": {"text": "The various offering in sleeping aids market", "keywords": [{"text": "various offering"}, {"text": "aids market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The global sleeping aids market", "keywords": [{"text": "global sleeping aids"}, {"text": "market"}]}, "sentence": " The global sleeping aids market is projected to grow at a decent pace for the next few years to cross the $100,0 billion mark by 2023.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global sleeping aids market", "keywords": [{"text": "global sleeping aids"}, {"text": "market"}]}, "sentence": " The global sleeping aids market is projected to grow at a decent pace for the next few years to cross the $100,0 billion mark by 2023.", "object": {"text": "at a decent pace", "keywords": [{"text": "decent pace"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is projected to grow", "normalized": "be project to grow"}}, {"subject": {"text": "The global sleeping aids market", "keywords": [{"text": "global sleeping aids"}, {"text": "market"}]}, "sentence": " The global sleeping aids market is projected to grow at a decent pace for the next few years to cross the $100,0 billion mark by 2023.", "object": {"text": "the $100,0 billion mark", "keywords": [{"text": "mark"}], "entities": [{"type": "Quantity", "text": "$100,0 billion"}]}, "action": {"verb": {"text": "cross", "tense": "future"}, "text": "to cross", "normalized": "to cross"}}, {"subject": {"text": "Side effects", "keywords": [{"text": "effects"}]}, "sentence": " Side effects associated with OTC sleep medications such as daytime drowsiness, dry mouth, headache and change in appetite have led to the shift in the preference of consumers towards herbal OTC drugs.", "object": {"text": "with OTC sleep medications such as daytime drowsiness", "keywords": [{"text": "daytime drowsiness"}, {"text": "OTC"}, {"text": "medications"}], "entities": [{"type": "HealthCondition", "text": "daytime drowsiness"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "Majority of consumers", "keywords": [{"text": "Majority"}, {"text": "consumers"}]}, "sentence": " Majority of consumers use herbal medicines in combination with both prescription and non-prescription drugs.", "object": {"text": "herbal medicines", "keywords": [{"text": "herbal medicines"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "use", "normalized": "use"}}, {"subject": {"text": "The patients", "keywords": [{"text": "patients"}]}, "sentence": " The patients specify that the use of herbal medicine demonstrates their independence in managing their health problems, thereby improving their general well-being.", "object": {"text": "that the use of herbal medicine demonstrates their independence in managing their health problems", "keywords": [{"text": "herbal medicine"}, {"text": "health problems"}, {"text": "independence"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "80% of the African populations", "keywords": [{"text": "African populations"}], "entities": [{"type": "Quantity", "text": "80"}]}, "sentence": " According to World Health Organization (WHO) bulletin, 80% of the African populations use some form of traditional herbal medicine, and the worldwide annual market for these products approached $60 billion in 2005.", "object": {"text": "some form of traditional herbal medicine, and the worldwide annual market", "keywords": [{"text": "traditional herbal medicine"}, {"text": "worldwide annual market"}, {"text": "form"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "use", "normalized": "use"}}, {"subject": {"text": "A National Poll on Healthy Aging (NPHA)", "keywords": [{"text": "Healthy Aging"}, {"text": "National Poll"}, {"text": "NPHA"}], "entities": [{"type": "Organization", "text": "NPHA"}]}, "sentence": " A National Poll on Healthy Aging (NPHA) was conducted by the University of Michigan, in 2017, which stated that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis, while another 8% said that they used these aids occasionally.*Browse report at: bit.ly/2plF4sD Growing healthcare facilities is driving the global sleeping aids market.", "object": {"text": "conducted by the University of Michigan, in 2017, which stated that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis", "keywords": [{"text": "herbal sleeping aids"}, {"text": "regular basis"}, {"text": "University"}, {"text": "Michigan"}], "entities": [{"type": "Organization", "text": "University of Michigan", "disambiguation": {"subtype": ["Location", "AcademicInstitution", "CollegeUniversity", "University"], "name": "University of Michigan", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Michigan"}}, {"type": "Quantity", "text": "80 years"}, {"type": "Quantity", "text": "4"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by the University of Michigan, in 2017, which stated that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis, while another 8% said that they used these aids occasionally.*Browse report at: bit.ly/2plF4sD Growing healthcare facilities is driving the global sleeping aids market", "keywords": [{"text": "herbal sleeping aids"}, {"text": "global sleeping aids"}, {"text": "bit.ly/2plF4sD Growing healthcare"}, {"text": "aids occasionally.*Browse report"}], "entities": [{"type": "Organization", "text": "University of Michigan", "disambiguation": {"subtype": ["Location", "AcademicInstitution", "CollegeUniversity", "University"], "name": "University of Michigan", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Michigan"}}, {"type": "Quantity", "text": "80 years"}, {"type": "Quantity", "text": "4"}, {"type": "Quantity", "text": "8"}]}, "sentence": " A National Poll on Healthy Aging (NPHA) was conducted by the University of Michigan, in 2017, which stated that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis, while another 8% said that they used these aids occasionally.*Browse report at: bit.ly/2plF4sD Growing healthcare facilities is driving the global sleeping aids market.", "object": {"text": "A National Poll on Healthy Aging (NPHA)", "keywords": [{"text": "Healthy Aging"}, {"text": "National Poll"}, {"text": "NPHA"}], "entities": [{"type": "Organization", "text": "NPHA"}]}, "action": {"verb": {"text": "conduct", "tense": "past"}, "text": "was conducted", "normalized": "be conduct"}}, {"subject": {"text": "the University of Michigan,", "keywords": [{"text": "University"}, {"text": "Michigan"}], "entities": [{"type": "Organization", "text": "University of Michigan", "disambiguation": {"subtype": ["Location", "AcademicInstitution", "CollegeUniversity", "University"], "name": "University of Michigan", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Michigan"}}]}, "sentence": " A National Poll on Healthy Aging (NPHA) was conducted by the University of Michigan, in 2017, which stated that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis, while another 8% said that they used these aids occasionally.*Browse report at: bit.ly/2plF4sD Growing healthcare facilities is driving the global sleeping aids market.", "object": {"text": "that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis", "keywords": [{"text": "herbal sleeping aids"}, {"text": "regular basis"}, {"text": "people"}], "entities": [{"type": "Quantity", "text": "80 years"}, {"type": "Quantity", "text": "4"}]}, "action": {"verb": {"text": "state", "tense": "past"}, "text": "stated", "normalized": "state"}}, {"subject": {"text": "another 8%", "entities": [{"type": "Quantity", "text": "8"}]}, "sentence": " A National Poll on Healthy Aging (NPHA) was conducted by the University of Michigan, in 2017, which stated that the people aged 65-80 years used 4% of the herbal sleeping aids on regular basis, while another 8% said that they used these aids occasionally.*Browse report at: bit.ly/2plF4sD Growing healthcare facilities is driving the global sleeping aids market.", "object": {"text": "that they used these aids occasionally.*Browse report at: bit.ly/2plF4sD Growing healthcare facilities is driving the global sleeping aids market", "keywords": [{"text": "global sleeping aids"}, {"text": "bit.ly/2plF4sD Growing healthcare"}, {"text": "aids occasionally.*Browse report"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "There"}, "sentence": " There has been an increase in the funding in healthcare sector to control sleep-related disorders such as insomnia, sleep apnea, and others.", "object": {"text": "been an increase in the funding in healthcare sector to control sleep-related disorders such as insomnia", "keywords": [{"text": "sleep-related disorders"}, {"text": "healthcare sector"}, {"text": "insomnia"}, {"text": "increase"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "an increase in the funding in healthcare sector", "keywords": [{"text": "healthcare sector"}, {"text": "increase"}, {"text": "funding"}]}, "sentence": " There has been an increase in the funding in healthcare sector to control sleep-related disorders such as insomnia, sleep apnea, and others.", "object": {"text": "to control sleep-related disorders such as insomnia, sleep apnea, and others", "keywords": [{"text": "sleep apnea"}, {"text": "sleep-related disorders"}, {"text": "insomnia"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "the government", "keywords": [{"text": "government"}]}, "sentence": " According to the Indian Medical Association, the government aims to increase the spending in healthcare up to 3.0% by 2022.", "object": {"text": "to increase the spending in healthcare up to 3.0% by 2022", "keywords": [{"text": "spending"}, {"text": "healthcare"}], "entities": [{"type": "Quantity", "text": "3.0"}]}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "the government", "keywords": [{"text": "government"}]}, "sentence": " According to the Indian Medical Association, the government aims to increase the spending in healthcare up to 3.0% by 2022.", "object": {"text": "the spending", "keywords": [{"text": "spending"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "aims to increase", "normalized": "aim to increase"}}, {"subject": {"text": "the demand for healthcare facilities in India", "keywords": [{"text": "demand"}, {"text": "healthcare facilities"}, {"text": "India"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Also, the demand for healthcare facilities in India is poised to reach to $280 billion in 2020, from $100 billion in 2016.", "object": {"text": "to reach to $280 billion in 2020, from $100 billion in 2016", "entities": [{"type": "Quantity", "text": "$100 billion"}, {"type": "Quantity", "text": "$280 billion"}]}, "action": {"verb": {"text": "poise", "tense": "past"}, "text": "poised", "normalized": "poise"}}, {"subject": {"text": "the enhancement of healthcare facilities", "keywords": [{"text": "enhancement"}, {"text": "healthcare facilities"}], "entities": []}, "sentence": " Other than that, manufacturers are also investing for the enhancement of healthcare facilities to control sleep-related disorders.", "object": {"text": "sleep-related disorders", "keywords": [{"text": "sleep-related disorders"}]}, "action": {"verb": {"text": "control", "tense": "future"}, "text": "to control", "normalized": "to control"}}, {"subject": {"text": "Royal Philips", "keywords": [{"text": "Royal"}], "entities": [{"type": "Company", "text": "Royal Philips"}]}, "sentence": " For instance, in March 2018, Royal Philips announced the opening of Southeast Asia\u00e2s first Sleep and Respiratory Education Center at its regional headquarters, the Philips APAC Center in Singapore.", "object": {"text": "the opening of Southeast Asia\u00e2s first Sleep and Respiratory Education Center at its regional headquarters, the Philips APAC Center in Singapore", "keywords": [{"text": "Philips APAC Center"}, {"text": "Respiratory Education Center"}, {"text": "Southeast Asia\u00e2s"}, {"text": "regional headquarters"}], "entities": [{"type": "Facility", "text": "Respiratory Education Center"}, {"type": "Organization", "text": "Philips APAC Center"}, {"type": "Location", "text": "Singapore", "disambiguation": {"subtype": ["City"], "name": "Singapore", "dbpedia_resource": "http://dbpedia.org/resource/Singapore"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "government as well as private/public firms", "keywords": [{"text": "private/public firms"}, {"text": "government"}]}, "sentence": " Thus, government as well as private/public firms are encouraging the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.", "object": {"text": "encouraging the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research", "keywords": [{"text": "sleep-related disorders.About P&S"}, {"text": "P&S Market Research"}, {"text": "IntelligenceP&S Intelligence"}, {"text": "facilitation"}], "entities": [{"type": "Company", "text": "P&S Market Research"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "government as well as private/public firms", "keywords": [{"text": "private/public firms"}, {"text": "government"}]}, "sentence": " Thus, government as well as private/public firms are encouraging the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.", "object": {"text": "the facilitation in healthcare", "keywords": [{"text": "facilitation"}, {"text": "healthcare"}]}, "action": {"verb": {"text": "encourage", "tense": "present"}, "text": "are encouraging", "normalized": "be encourage"}}, {"subject": {"text": "the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research,", "keywords": [{"text": "sleep-related disorders.About P&S"}, {"text": "P&S Market Research"}, {"text": "IntelligenceP&S Intelligence"}, {"text": "facilitation"}], "entities": [{"type": "Company", "text": "P&S Market Research"}]}, "sentence": " Thus, government as well as private/public firms are encouraging the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.", "object": {"text": "a provider of market research", "keywords": [{"text": "market research"}, {"text": "provider"}], "entities": [{"type": "Company", "text": "P&S Market Research"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a brand of P&S Market Research,", "keywords": [{"text": "P&S Market Research"}, {"text": "brand"}], "entities": [{"type": "Company", "text": "P&S Market Research"}]}, "sentence": " Thus, government as well as private/public firms are encouraging the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.", "object": {"text": "services catering", "keywords": [{"text": "services catering"}], "entities": [{"type": "Company", "text": "Singapore Health Services", "disambiguation": {"subtype": ["Company"], "name": "SingHealth", "dbpedia_resource": "http://dbpedia.org/resource/SingHealth"}}]}, "action": {"verb": {"text": "consult", "tense": "present"}, "text": "consulting", "normalized": "consult"}}, {"subject": {"text": "a provider of market research and consulting services catering to the market information", "keywords": [{"text": "market research"}, {"text": "market information"}, {"text": "provider"}, {"text": "services"}], "entities": [{"type": "Company", "text": "P&S Market Research"}, {"type": "Company", "text": "Singapore Health Services", "disambiguation": {"subtype": ["Company"], "name": "SingHealth", "dbpedia_resource": "http://dbpedia.org/resource/SingHealth"}}]}, "sentence": " Thus, government as well as private/public firms are encouraging the facilitation in healthcare for the treatment of sleep-related disorders.About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.", "object": {"text": "of burgeoning industries", "keywords": [{"text": "industries"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "P&S", "keywords": [{"text": "P&S"}]}, "sentence": " Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "object": {"text": "the plinth", "keywords": [{"text": "plinth"}]}, "action": {"verb": {"text": "Providing", "tense": "present"}, "text": "Providing", "normalized": "Providing"}}, {"subject": {"text": "Providing the plinth of market intelligence, P&S as an enterprising research and consulting company,", "keywords": [{"text": "enterprising research"}, {"text": "market intelligence"}, {"text": "plinth"}, {"text": "P&S"}]}, "sentence": " Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "object": {"text": "in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "keywords": [{"text": "ever-changing market scenario"}, {"text": "thorough landscape analyses"}, {"text": "United States Toll-free"}, {"text": "New York City"}], "entities": [{"type": "Location", "text": "New York City", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believes", "normalized": "believe"}}, {"subject": {"text": "thorough landscape analyses", "keywords": [{"text": "thorough landscape analyses"}]}, "sentence": " Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "decisions", "keywords": [{"text": "decisions"}]}, "sentence": " Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "object": {"text": "with astuteness.Contact", "keywords": [{"text": "astuteness.Contact"}]}, "action": {"verb": {"text": "inform", "tense": "past"}, "text": "informed", "normalized": "inform"}}], "concepts": [{"text": "Sleep apnea", "relevance": 0.962714, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_apnea"}, {"text": "Sleep", "relevance": 0.81081, "dbpedia_resource": "http://dbpedia.org/resource/Sleep"}, {"text": "Sleep disorder", "relevance": 0.653431, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_disorder"}, {"text": "Sleep medicine", "relevance": 0.592186, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_medicine"}, {"text": "Sleep deprivation", "relevance": 0.589175, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_deprivation"}, {"text": "Polysomnography", "relevance": 0.57669, "dbpedia_resource": "http://dbpedia.org/resource/Polysomnography"}, {"text": "Medicine", "relevance": 0.528531, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Obstructive sleep apnea", "relevance": 0.527667, "dbpedia_resource": "http://dbpedia.org/resource/Obstructive_sleep_apnea"}, {"text": "Narcolepsy", "relevance": 0.469766, "dbpedia_resource": "http://dbpedia.org/resource/Narcolepsy"}, {"text": "American Academy of Sleep Medicine", "relevance": 0.442839, "dbpedia_resource": "http://dbpedia.org/resource/American_Academy_of_Sleep_Medicine"}, {"text": "World Health Organization", "relevance": 0.415334, "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}, {"text": "Circadian rhythm", "relevance": 0.410291, "dbpedia_resource": "http://dbpedia.org/resource/Circadian_rhythm"}, {"text": "Health care", "relevance": 0.405659, "dbpedia_resource": "http://dbpedia.org/resource/Health_care"}, {"text": "Herbal medicine", "relevance": 0.397845, "dbpedia_resource": "http://dbpedia.org/resource/Herbal_medicine"}, {"text": "Insomnia", "relevance": 0.371758, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Sleep disorders", "relevance": 0.368569, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_disorders"}, {"text": "Excessive daytime sleepiness", "relevance": 0.360003, "dbpedia_resource": "http://dbpedia.org/resource/Excessive_daytime_sleepiness"}, {"text": "Marketing", "relevance": 0.356912, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Hypopnea", "relevance": 0.355445, "dbpedia_resource": "http://dbpedia.org/resource/Hypopnea"}, {"text": "Philips", "relevance": 0.348118, "dbpedia_resource": "http://dbpedia.org/resource/Philips"}, {"text": "Sleep hygiene", "relevance": 0.344176, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_hygiene"}, {"text": "Somnolence", "relevance": 0.328915, "dbpedia_resource": "http://dbpedia.org/resource/Somnolence"}, {"text": "Over-the-counter drug", "relevance": 0.326617, "dbpedia_resource": "http://dbpedia.org/resource/Over-the-counter_drug"}, {"text": "Pharmacology", "relevance": 0.326396, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Sudden infant death syndrome", "relevance": 0.32154, "dbpedia_resource": "http://dbpedia.org/resource/Sudden_infant_death_syndrome"}, {"text": "Health care provider", "relevance": 0.306139, "dbpedia_resource": "http://dbpedia.org/resource/Health_care_provider"}, {"text": "Sleep physiology", "relevance": 0.286658, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_physiology"}, {"text": "Merck KGaA", "relevance": 0.285706, "dbpedia_resource": "http://dbpedia.org/resource/Merck_KGaA"}, {"text": "Healthcare", "relevance": 0.276706, "dbpedia_resource": "http://dbpedia.org/resource/Healthcare"}, {"text": "Preference", "relevance": 0.271031, "dbpedia_resource": "http://dbpedia.org/resource/Preference"}, {"text": "Abnormal respiration", "relevance": 0.268934, "dbpedia_resource": "http://dbpedia.org/resource/Abnormal_respiration"}, {"text": "Apnea", "relevance": 0.267397, "dbpedia_resource": "http://dbpedia.org/resource/Apnea"}, {"text": "Pharmaceutical drug", "relevance": 0.265313, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Health", "relevance": 0.261304, "dbpedia_resource": "http://dbpedia.org/resource/Health"}], "categories": [{"score": 0.999268, "label": "/health and fitness/disorders/sleep disorders"}, {"score": 0.624933, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Growing prevalence of insomnia and obstructive sleep apnea (OSA) disorders, rising use of portable sleep apnea devices, increasing government support for start-up companies, growing healthcare facilities, surge in the demand for sleeping pills attributed to stressful modern lifestyle, and increasing geriatric population are the key factors driving the growth of the market.*Explore report sample at: bit.ly/2laOHZI Some of the key players in sleeping aids industry are Sanofi, Merck KGaA, Koninklijke Philips N.V., Pfizer Inc., SleepMed Inc., Takeda Pharmaceutical Co. Ltd., Cadwell Laboratories Inc., Natus Medical Inc., and Compumedics Limited.Shifting consumer preference toward herbal OTC drugs is a major trend in the sleeping aids market.", "score": 0.408005, "arguments": [{"text": "companies", "location": [596, 605], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "healthcare facilities", "location": [615, 636], "entities": [{"type": "Facility", "text": "healthcare facilities"}]}]}, {"type": "ownerOf", "sentence": "For instance, in March 2018, Royal Philips announced the opening of Southeast Asia\u00e2s first Sleep and Respiratory Education Center at its regional headquarters, the Philips APAC Center in Singapore.", "score": 0.59338, "arguments": [{"text": "its", "location": [2884, 2887], "entities": [{"type": "Organization", "text": "Respiratory Education Center"}]}, {"text": "headquarters", "location": [2897, 2909], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "residesIn", "sentence": "In the new facility, Philips would work with international sleep and respiratory physicians and partners such as Singapore Health Services (SingHealth), to train healthcare professionals from across the region to better diagnose and treat sleep disorders.", "score": 0.334397, "arguments": [{"text": "partners", "location": [3045, 3053], "entities": [{"type": "Person", "text": "professionals"}]}, {"text": "Singapore", "location": [3062, 3071], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "In the new facility, Philips would work with international sleep and respiratory physicians and partners such as Singapore Health Services (SingHealth), to train healthcare professionals from across the region to better diagnose and treat sleep disorders.", "score": 0.486111, "arguments": [{"text": "partners", "location": [3045, 3053], "entities": [{"type": "Person", "text": "professionals"}]}, {"text": "Health Services", "location": [3072, 3087], "entities": [{"type": "Organization", "text": "Health Services"}]}]}, {"type": "basedIn", "sentence": "In the new facility, Philips would work with international sleep and respiratory physicians and partners such as Singapore Health Services (SingHealth), to train healthcare professionals from across the region to better diagnose and treat sleep disorders.", "score": 0.899756, "arguments": [{"text": "Health Services", "location": [3072, 3087], "entities": [{"type": "Organization", "text": "Health Services"}]}, {"text": "Singapore", "location": [3062, 3071], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "In the new facility, Philips would work with international sleep and respiratory physicians and partners such as Singapore Health Services (SingHealth), to train healthcare professionals from across the region to better diagnose and treat sleep disorders.", "score": 0.403794, "arguments": [{"text": "professionals", "location": [3122, 3135], "entities": [{"type": "Person", "text": "professionals"}]}, {"text": "region", "location": [3152, 3158], "entities": [{"type": "Location", "text": "region"}]}]}, {"type": "locatedAt", "sentence": "About P&S IntelligenceP&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.", "score": 0.702852, "arguments": [{"text": "burgeoning", "location": [3519, 3529], "entities": [{"type": "Crime", "text": "burgeoning"}]}, {"text": "world", "location": [3552, 3557], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "residesIn", "sentence": "Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "score": 0.859634, "arguments": [{"text": "Ave. #1402", "location": [3864, 3874], "entities": [{"type": "Person", "text": "Ave. #1402"}]}, {"text": "New York City", "location": [3880, 3893], "entities": [{"type": "GeopoliticalEntity", "text": "New York City"}]}]}, {"type": "locatedAt", "sentence": "Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "score": 0.954561, "arguments": [{"text": "New York City", "location": [3880, 3893], "entities": [{"type": "GeopoliticalEntity", "text": "New York City"}]}, {"text": "NY", "location": [3895, 3897], "entities": [{"type": "GeopoliticalEntity", "text": "NY"}]}]}, {"type": "employedBy", "sentence": "Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact: 347 5th Ave. #1402- 210 New York City, NY 10016 United States Toll-free: +1-888-778-7886 (USA/Canada)", "score": 0.570299, "arguments": [{"text": "Toll", "location": [3918, 3922], "entities": [{"type": "Person", "text": "Toll"}]}, {"text": "United States", "location": [3904, 3917], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Majority of consumers use herbal medicines in combination with both prescription and non-prescription drugs.", "score": 0.981901, "arguments": [{"text": "Majority", "location": [1381, 1389], "entities": [{"type": "Cardinal", "text": "Majority"}]}, {"text": "consumers", "location": [1393, 1402], "entities": [{"type": "Person", "text": "consumers"}]}]}, {"type": "employedBy", "sentence": "According to World Health Organization (WHO) bulletin, 80% of the African populations use some form of traditional herbal medicine, and the worldwide annual market for these products approached $60 billion in 2005.", "score": 0.425848, "arguments": [{"text": "WHO", "location": [1694, 1697], "entities": [{"type": "Person", "text": "WHO"}]}, {"text": "World Health Organization", "location": [1667, 1692], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "basedIn", "sentence": "According to World Health Organization (WHO) bulletin, 80% of the African populations use some form of traditional herbal medicine, and the worldwide annual market for these products approached $60 billion in 2005.", "score": 0.462164, "arguments": [{"text": "populations", "location": [1728, 1739], "entities": [{"type": "Organization", "text": "populations"}]}, {"text": "African", "location": [1720, 1727], "entities": [{"type": "GeopoliticalEntity", "text": "professionals"}]}]}, {"type": "basedIn", "sentence": "According to the Indian Medical Association, the government aims to increase the spending in healthcare up to 3.0% by 2022.", "score": 0.860523, "arguments": [{"text": "Medical Association", "location": [2397, 2416], "entities": [{"type": "Organization", "text": "Medical Association"}]}, {"text": "Indian", "location": [2390, 2396], "entities": [{"type": "GeopoliticalEntity", "text": "Indian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Also, the demand for healthcare facilities in India is poised to reach to $280 billion in 2020, from $100 billion in 2016.", "score": 0.961789, "arguments": [{"text": "healthcare facilities", "location": [2518, 2539], "entities": [{"type": "Facility", "text": "healthcare facilities"}]}, {"text": "India", "location": [2543, 2548], "entities": [{"type": "GeopoliticalEntity", "text": "Indian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Other than that, manufacturers are also investing for the enhancement of healthcare facilities to control sleep-related disorders.", "score": 0.278097, "arguments": [{"text": "manufacturers", "location": [2637, 2650], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "healthcare facilities", "location": [2693, 2714], "entities": [{"type": "Facility", "text": "healthcare facilities"}]}]}, {"type": "timeOf", "sentence": "For instance, in March 2018, Royal Philips announced the opening of Southeast Asia\u00e2s first Sleep and Respiratory Education Center at its regional headquarters, the Philips APAC Center in Singapore.", "score": 0.832998, "arguments": [{"text": "March 2018", "location": [2768, 2778], "entities": [{"type": "Date", "text": "March 2018"}]}, {"text": "announced", "location": [2794, 2803], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "For instance, in March 2018, Royal Philips announced the opening of Southeast Asia\u00e2s first Sleep and Respiratory Education Center at its regional headquarters, the Philips APAC Center in Singapore.", "score": 0.99223, "arguments": [{"text": "Royal Philips", "location": [2780, 2793], "entities": [{"type": "Organization", "text": "Royal Philips", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [2794, 2803], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}], "keywords": [{"text": "sleep laboratory services", "sentiment": {"score": 0.466427, "label": "positive"}, "relevance": 0.744871, "count": 1}, {"text": "healthcare facilities", "sentiment": {"score": 0.288002, "mixed": "1", "label": "positive"}, "relevance": 0.641648, "count": 3}, {"text": "aids market", "sentiment": {"score": 0.466427, "label": "positive"}, "relevance": 0.638547, "count": 1}, {"text": "sleep apnea devices", "sentiment": {"score": 0.466427, "label": "positive"}, "relevance": 0.621842, "count": 1}, {"text": "global sleeping aids market", "sentiment": {"score": -0.684272, "mixed": "1", "label": "negative"}, "relevance": 0.600794, "count": 2}, {"text": "government support", "sentiment": {"score": -0.885043, "label": "negative"}, "relevance": 0.600022, "count": 1}, {"text": "obstructive sleep apnea", "sentiment": {"score": -0.885043, "label": "negative"}, "relevance": 0.582656, "count": 1}, {"text": "P&S IntelligenceP", "sentiment": {"score": 0.992907, "label": "positive"}, "relevance": 0.574659, "count": 1}, {"text": "use of portable sleep apnea devices", "sentiment": {"score": -0.885043, "label": "negative"}, "relevance": 0.574142, "count": 1}, {"text": "medical devices", "sentiment": {"score": -0.561563, "label": "negative"}, "relevance": 0.573963, "count": 1}, {"text": "aids", "sentiment": {"score": -0.561563, "label": "negative"}, "relevance": 0.562735, "count": 2}, {"text": "National Poll", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561967, "count": 1}, {"text": "Press release", "sentiment": {"score": -0.561563, "label": "negative"}, "relevance": 0.561886, "count": 1}, {"text": "brand of P&S Market Research", "sentiment": {"score": 0.992907, "label": "positive"}, "relevance": 0.556922, "count": 1}, {"text": "health problems", "sentiment": {"score": 0.766355, "label": "positive"}, "relevance": 0.55189, "count": 1}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549696, "count": 1}, {"text": "government", "sentiment": {"score": 0.992907, "label": "positive"}, "relevance": 0.548412, "count": 2}, {"text": "herbal OTC drugs", "sentiment": {"score": -0.544582, "mixed": "1", "label": "negative"}, "relevance": 0.546529, "count": 2}, {"text": "herbal medicines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546512, "count": 1}, {"text": "business strategies", "sentiment": {"score": 0.886732, "label": "positive"}, "relevance": 0.545638, "count": 1}, {"text": "companies", "sentiment": {"score": 0.297601, "mixed": "1", "label": "positive"}, "relevance": 0.545049, "count": 2}, {"text": "company", "sentiment": {"score": 0.886732, "label": "positive"}, "relevance": 0.545049, "count": 1}, {"text": "World Health Organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543705, "count": 1}, {"text": "Koninklijke Philips N.V.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543328, "count": 1}, {"text": "Merck KGaA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539929, "count": 1}, {"text": "regular basis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533355, "count": 1}, {"text": "sleep apnea", "sentiment": {"score": -0.950297, "label": "negative"}, "relevance": 0.531279, "count": 1}, {"text": "sleeping aids market", "sentiment": {"score": -0.544582, "mixed": "1", "label": "negative"}, "relevance": 0.530978, "count": 1}, {"text": "African populations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529985, "count": 1}, {"text": "disorders", "sentiment": {"score": -0.885043, "label": "negative"}, "relevance": 0.529204, "count": 1}, {"text": "healthcare", "sentiment": {"score": 0.992907, "label": "positive"}, "relevance": 0.529187, "count": 2}, {"text": "regional headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52709, "count": 1}, {"text": "instance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526897, "count": 1}, {"text": "Strategic Intelligence", "sentiment": {"score": -0.561563, "label": "negative"}, "relevance": 0.526184, "count": 1}, {"text": "others", "sentiment": {"score": 0.466427, "label": "positive"}, "relevance": 0.526074, "count": 2}, {"text": "healthcare professionals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52577, "count": 1}, {"text": "sleep disorders", "sentiment": {"score": 0.992907, "label": "positive"}, "relevance": 0.524708, "count": 1}, {"text": "report", "sentiment": {"score": 0.481657, "label": "positive"}, "relevance": 0.524238, "count": 1}, {"text": "growth of the market", "sentiment": {"score": -0.888685, "label": "negative"}, "relevance": 0.523071, "count": 1}, {"text": "Sleep", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522997, "count": 1}, {"text": "bit", "sentiment": {"score": 0.481657, "label": "positive"}, "relevance": 0.522732, "count": 2}, {"text": "medication", "sentiment": {"score": 0.466427, "label": "positive"}, "relevance": 0.521643, "count": 1}, {"text": "demand", "sentiment": {"score": -0.345415, "mixed": "1", "label": "negative"}, "relevance": 0.52073, "count": 2}, {"text": "sleep-related disorders", "sentiment": {"score": -0.813477, "label": "negative"}, "relevance": 0.51959, "count": 2}, {"text": "services", "sentiment": {"score": 0.992907, "label": "positive"}, "relevance": 0.518432, "count": 1}, {"text": "Philips", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518332, "count": 1}, {"text": "insomnia", "sentiment": {"score": -0.950297, "label": "negative"}, "relevance": 0.517703, "count": 1}, {"text": "industries", "sentiment": {"score": 0.945172, "label": "positive"}, "relevance": 0.517246, "count": 1}, {"text": "decisions", "sentiment": {"score": 0.886732, "label": "positive"}, "relevance": 0.517116, "count": 1}, {"text": "base", "sentiment": {"score": 0.886732, "label": "positive"}, "relevance": 0.516853, "count": 1}]}, "extracted_metadata": {"sha1": "a163fe3756c0b4520efc770d724e8f105627fbc5", "filename": "1542906385144.zip-122929c068c274810870a10fdae4a5a0.xml", "file_type": "json"}, "external_links": ["http://bit.ly/2laOHZI", "http://bit.ly/2plF4sD"], "title": "Sleeping Aids Market 2023 by Key Players Merck Group, Pfizer, Natus Medical Incorporated, Compumedics Limited - Official", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}]}